The Evolving Global Landscape in Vaccine Development: Novotech and Endpoints News Webinar ACN Newswire

The Evolving Global Landscape in Vaccine Development: Novotech and Endpoints News Webinar

February 15, 2023
SYDNEY, AU, Feb 15, 2023 - (ACN Newswire via SEAPRWire.com) - Novotech, the leading Asia Pacific centred biotech CRO with extensive experience in vaccine trials, is convening an expert panel webinar covering the evolving landscape in vaccine development.Register here https://webinars.endpts.com/keeping-pace-with-the-evolving-global-landscape-in-vaccine-development/ Between 2017 and 2021, there were close to 1,400 industry-sponsored single country vaccine based clinical trials globally, with the Asia Pacific involved in over 45% of the trials. Download our latest data report here: Vaccines - Asia Pacific Clinical Trial Landscape. https://novotech-cro.com/whitepapers/vaccines-asia-pacific-clinical-trial-landscapeThe webinar, Keeping pace with the evolving global landscape in vaccine development, will hear from a panel of life science experts on the latest advancements and innovative modalities paving the way in the global vaccine development space including:- The COVID-19 impact on drug development and the regulatory landscape. - Key factors contributing to Asia Pacific being recognised as the hub for vaccine development and opportunities for biotech's to leverage. - Key considerations for pre-clinical and clinical planning to accelerate vaccine development, supporting a robust global strategy.Date/Time: March 09 11:00 am - 12:00 pm ESTRegister here https://webinars.endpts.com/keeping-pace-with-the-evolving-global-landscape-in-vaccine-development/Panelists:SUSHANT SAHASTRABUDDHEASSOCIATE DIRECTOR GENERAL, INTERNATIONAL VACCINE INSTITUTE (IVI)Dr. Sushant Sahastrabuddhe, Associate Director General at the International Vaccine Institute (IVI), joined in July 2010, leading the clinical trials of IVI's typhoid vaccine and process to achieve its licensure, the global clinical development of and licensure of SK bioscience's COVID-19 vaccines and Phase 1 and 2 trials of Bharat Biotech's Chikungunya vaccine. As a vaccine enthusiast with more than 17 years of experience in multiple countries across diverse projects, he continues to lead collaborative efforts with companies and partners in Korea, India and globally to get these vaccines through early- to late-stages of their clinical development. Dr. Sahastrabuddhe is also the Associate Editor for Vaccines for tropical diseases and associated with Yonsei University as Research Professor and with Universite Claude Bernanrd, Lyon France as Research Fellow. In 2021, Dr. Sahastrabuddhe was named an 'Honorary Citizen of Seoul' for his contributions to the joint efforts with Korean companies and international partners to develop vaccines against COVID-19 and other diseases.PAUL GRIFFINASSOCIATE PROFESSOR, INFECTIOUS DISEASES PHYSICIAN, MICROBIOLOGIST, UNIVERSITY OF QUEENSLANDAn Infectious Diseases Physician and Microbiologist, Dr. Paul Griffin was appointed as the Director of Infectious Diseases at Mater Health Services in 2013 and continues an appointment as an Associate Professor of Medicine at the University of Queensland Medical School. Additionally, Dr. Griffin chairs the Advanced Training Committee in Infectious Diseases with the Royal Australasian College of Physicians, the committee that oversees the training of Infectious Diseases specialists in Australia.Previously, Dr. Griffin was the Principal Investigator (PI) and Medical Director at Nucleus Network, a contract research organization specializing in infectious diseases trials, which included a PI role on in excess of 125 clinical trials predominantly in Infectious Diseases including novel vaccines and COVID-19 vaccines. With fellowships in Infectious Diseases from the Royal Australasian College of Physicians, in Clinical Microbiology from the Royal College of Pathologists of Australasia and from the Australasian College of Tropical Medicine, Dr. Griffin has an active interest in vaccine education and advocacy and has become a trusted media authority and spokesperson across the nation during the COVID-19 pandemic.BABAJI YADAVSENIOR CONSULTANT, NOVOTECH DRUG DEVELOPMENT CONSULTINGBabaji Yadav is a Senior Consultant with over eight years of academic experience in pre-clinical oncology drug development and eight years of industry experience in drug development. Babaji has a strong background in pharmaceutical sciences with a Ph.D. in Pharmacology and Toxicology from the University of Otago, New Zealand. Previously he has worked as a Research Project Manager to oversee IND-enabling toxicology studies for lead oncology drugs and, prior to joining Novotech, was a Clinical Project Manager for early-phase oncology trials. Babaji is a UK Registered Toxicologist and at Novotech he is focused on providing technical toxicology advice and product development strategies to facilitate the entry of client's compounds into clinical trials. Babaji has experience in small molecules, combination products, and biologicals including vaccines, proteins, monoclonal antibodies, and advanced cell and gene therapies.JENNIFER ARELLANODIRECTOR OF CLINICAL SERVICES (PHILIPPINES), NOVOTECHJennifer Arellano is the Director of Clinical Services in the Philippines with over 25 years of technical and leadership experience in managing clinical trial operations for sponsors and CROs. With a Bachelor of Industrial Pharmacy from the University of the Philippines and a Pharmacist license, Jennifer's research operations experience includes monitoring, auditing, project leadership, feasibility, study start-up, driving inspection readiness and hosting regulatory inspection, client engagement and business development, learning & development and organization SOP development/review. Jennifer has contributed to the transformation of the Philippine clinical research industry - bringing improvement to the local clinical research regulations and practices and is the founding President of a non-profit organization, the Philippine Clinical Research Professionals Inc, with more than 400 members from pharmaceutical and CROs, and has more recently, volunteered pro-bono services during the Covid-19 pandemic to provide trial management consultancy to the Philippine DOH-funded trials such as WHO Solidarity COVID-19 Treatment and Vaccine trials, Avigan COVID-19 treatment trial, and Philippine Heart Association funded cardiovascular outcome study.Novotech has recently acquired EastHORN, a European CRO with clinical, medical and regulatory expertise in multiple strategically important locations across the continent. The acquisition is part of Novotech's global expansion program in Europe and the US.Novotech has recently been benchmarked as a top 10 CRO among the world's leading CROs, is the recipient of the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence award and the Asia-Pacific Contract Research Organization Company of the Year Award, and has signed 45 Leading Site Partnership agreements over the last 3 years.Novotech offers biotechs a unique and unparalleled suite of early to late-phase CRO services across Europe and the US, with a specialist focus on Asia Pacific where the company has built a reputation for delivering high-quality expedited clinical trials. About Novotech (Novotech-CRO.com)Novotech is internationally recognized as the leading Asia Pacific centred biotech Contract Research Organization (CRO) with global execution capabilities. Novotech is a clinical CRO with labs, phase I facilities, drug development consulting services and FDA regulatory expertise and has experience in over 3,700 pre-clinical and clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. Novotech is positioned to serve biotech clients conducting clinical trials in Asia Pacific, the US and Europe. Novotech has over 2,700 staff working across offices in 20 geographies. For more information visit https://novotech-cro.com/contactMedia ContactDavid JamesE: communications@novotech-cro.comAU: +61 2 8218 2144 USA: +1 415 951 3228Asia: +65 3159 3427 Copyright 2023 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Honda to Make Organizational Changes (Effective April 1, 2023) to Further Accelerate Electrification Business and Realize New Value Creation JCN Newswire

Honda to Make Organizational Changes (Effective April 1, 2023) to Further Accelerate Electrification Business and Realize New Value Creation

January 24, 2023
TOKYO, Jan 24, 2023 - (JCN Newswire via SEAPRWire.com) - Honda Motor Co., Ltd. today announced that the company will make organizational and operational changes, effective April 1, 2023, as it continues working toward the fulfillment of its vision to serve people worldwide with the "joy of expanding their life's potential" in the areas of mobility and people's daily lives.With this year's changes, Honda will further solidify the direction of the organizational changes made last year with an eye toward the realization of carbon neutrality by 2050. Specifically, Honda will strive to further accelerate its electrification business and create new value by leveraging its broad and expanding range of mobility products and services.Key points of the organizational changes1) Creation of Electrification Business Development Operations2) Reorganization of Regional Operations3) Reorganization of Corporate FunctionsDetails of the organizational changes1) Creation of Electrification Business Development OperationsBased on the Business Development Operations established April last year to strengthen electrification business, the Electrification Business Development Operations will be newly created. This operation will consolidate the business strategy and BEV product development functions of automobile business and electrification-related strategy and development functions of motorcycle and power products businesses to further strengthen and accelerate Honda?s electrification business.2) Reorganization of Regional OperationsThe current six regional operations will be consolidated into three regional operations -- North America, China and Associated Regions.The new Regional Operations (Associated Regions) will combine four current regional operations, namely Japan, Asia & Oceania, South America and the Europe, Africa and the Middle East Region. With this change, Honda will execute electrification strategies and strengthen operations for each region based on its global strategy.3) Reorganization of Corporate FunctionsThe Corporate Strategy Operations and Corporate Administration Operations will be newly created. The Corporate Strategy Operations will further strengthen Honda?s initiatives in formulating, executing and communicating its corporate strategies toward new value creation, and the Corporate Administration Operations will pursue the total optimization of corporate resources, which is aligned with corporate strategy.By further accelerating the series of initiatives Honda has been taking to transform itself through electrification and new value creation, Honda strives to remain and become even more recognized as ?a company society wants to exist? in the electrified era. Copyright 2023 JCN Newswire. All rights reserved. (via SEAPRWire)
More
SinoHytec Successfully Listed on the Main Board of HKEX ACN Newswire

SinoHytec Successfully Listed on the Main Board of HKEX

January 12, 2023
HONG KONG, Jan 12, 2023 - (ACN Newswire via SEAPRWire.com) - The leading provider of fuel cell systems in China - Beijing SinoHytec Co., Ltd. ("SinoHytec" or the "Company", Stock Code: 2402), has successfully listed and commenced dealings on the Main Board of the Stock Exchange of Hong Kong Limited ("Hong Kong Stock Exchange" or "HKEX") today, under the stock code of 2402 and the Offer Price is HK$60 per Share in board lots of 50 shares each.SinoHytec is listed on the main board of HKEX, with 17,628,000 shares being offered globally, Among them, the International Offering was moderately over-subscribed, representing approximately 1.84 times the total number of 15,865,200 Offer Shares initially available under the International Offering.The Hong Kong Public Offering was slightly over-subscribed, representing approximately 0.29 times the total number of 1,762,800 Offer Shares initially available for subscription under the Hong Kong Public Offering.The net proceeds from the Global Offering to be received by the Company is estimated to be approximately HK$982.8million, after deduction of the underwriting commissions, fees and other estimated expenses payable in connection with the Global Offering, of which approximately 75% of the net proceeds received from the Global Offering will be used to fund the Company's research and development in the next three years; and about 15% will be used to enhance the Company's brand recognition through product promotion and multi-channel marketing in the next three years; the remaining approximately 10.0% will be used for working capital and other general corporate purposes.SinoHytec adheres to the R&D principles of "Advance Research", "Continuous Development" and "In-depth Promotion". Following a vertically integrated R&D path, it has evolved from integrating the fuel cell system into the fuel cell powertrain assembly, to developing and manufacturing the fuel cell system and the stack, and most recently the bipolar plate (the core component of the stack). In addition, the Company plans to develop and manufacture membrane electrodes, another major fuel cell stack component, through its main associate company, Shanghai Maximfuelcell Technology Co., Ltd.In addition to independent research and development, the Company jointly undertakes research and development projects and jointly develops fuel cell vehicles with research institutions, government departments and well-known automobile manufacturers. The Company's industry competitive advantages derive from its continuous leading position in the fast-growing Chinese fuel cell system market, strong R&D strength, established stable cooperative relations with domestic mainstream commercial vehicle companies, integrated parts supply system and established in-depth cooperation relations with suppliers, as well as the support of experienced senior management team and high-quality staff team, which will help the Company stand out from its many opponents.Mr. Zhang Guoqiang, Chairman, Executive Director and General Manager of SinoHytec said: "Today, SinoHytec is officially listed on the Main Board of the Hong Kong Stock Exchange, which is an important milestone in the Company's development and marks the entry of SinoHytec into the international capital market. We would like to express our gratitude to our investors for their trust and support of SinoHytec. Setting off from a new starting point, we will further promote the research and development of fuel cell systems and core components; Expand the production capacity of fuel cell stacks to meet the growing market demand and achieve economies of scale; economies of scale; strategically expand customer base and regional coverage; expand and strengthen the supply chain; and enhance brand awareness and promote the application of fuel cell systems. We will grasp the future trends and directions of the industry, and leverage our own competitive advantages to further consolidate SinoHytec's market position to create the greatest value for shareholders and investors." Copyright 2023 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Research commenced with Keio University to discover drugs using “Chemicals Informatics” JCN Newswire

Research commenced with Keio University to discover drugs using “Chemicals Informatics”

January 12, 2023
TOKYO, Jan 12, 2023 - (JCN Newswire via SEAPRWire.com) - Hitachi High-Tech Solutions Corporation, in collaboration with Keio University Faculty of Pharmacy, Department of Pharmaceutical Sciences is commencing joint research that uses Materials Informatics (MI) (the Research) to improve the efficiency of the development of small molecule drugs(1).Hitachi High-Tech Solutions will be using the "Chemicals Informatics (CI)" MI tool not only by developing materials in the traditional chemical materials field but also in the field of drug discovery, to improve quality of care and QoL (Quality of Life) for people.Background to the ResearchSmall molecule drugs are mainstream drugs in the modern world, and in recent years, expectations for their use have increased, with the development of drugs such as molecular-targeted drugs that inhibit the action of proteins, which cause cancer(2). Traditionally, the process used to develop small molecule drugs has involved researchers using their knowledge and experience to select several potential compounds from an extensive library of existing compounds and then repeating experiments to adjust the structure of a compound and clarify the mechanism by which it will work, before moving on to clinical trial. As a result, more than a decade's worth of R&D has been conducted at a huge cost, with a very low success rate. MI is expected to solve these challenges by using information science techniques, such as AI, to improve the efficiency of compound and material development.Overview of the ResearchIn the Research, Keio University Faculty of Pharmacy, Department of Pharmaceutical Sciences will use Hitachi High-Tech Solutions' CI to study the development of new drugs to act as selective inhibitors that will block enzymes that produce active sulfur molecules. We know that the production of a large quantity of active sulfur molecules in cells shows antioxidant effects, protein activity control and the generation of energy, etc. The development of small molecule drugs that inhibit the function of these enzymes is expected to lead to the elucidation of biological phenomena and the treatment of diseases such as cancer. The Research will use AI to conduct fast, comprehensive searches for promising compounds and potential structures based on the vast amount of data on compounds recorded in the CI, and then predict how the effects and mechanism will work using molecular dynamic simulations. This will help to improve the development of small molecule drugs in terms of a more efficient process, faster time scales and higher success rates, and will contribute to the development and early commercialization of new drugs.Through this Research, Hitachi High-Tech Group will provide a practical demonstration of how CI, which to date has helped develop various materials in the chemical materials industry, can be applied to the development of pharmaceuticals and contribute to new drug development initiatives. In so doing, we will provide optimal solutions for creating social value and contribute to improving people's QoL (Quality of Life).(1) Small molecule drug: A type of drug that has very small (low weight) molecules that are able to easily enter cells.(2) Molecular-targeted drugs: A therapeutic agent designed to act only on specific molecules that cause disease.About Hitachi High-TechHitachi High-Tech, headquartered in Tokyo, Japan, is engaged in activities in a broad range of fields, including manufacture and sales of clinical analyzers, biotechnology products, and analytical instruments, semiconductor manufacturing equipment and analysis equipment. and providing high value-added solutions in fields of social & industrial infrastructures and mobility, etc. The company's consolidated revenues for FY 2021 were approx. JPY 576.8 billion [USD 5.1 billion]. For further information, visit www.hitachi-hightech.com/global/Contact:Kurokawa, HoriuchiDX Marketing Dept., Corporate Strategy Div.,Hitachi High-Tech Solutions CorporationE-mail: hsl_marketing.dg@hitachi-hightech.com Copyright 2023 JCN Newswire. All rights reserved. (via SEAPRWire)
More
Novotech Acquires US-based Drug Development Consulting Firm, CBR International ACN Newswire

Novotech Acquires US-based Drug Development Consulting Firm, CBR International

January 12, 2023
SINGAPORE, Jan 12, 2023 - (ACN Newswire via SEAPRWire.com) - Novotech, the leading Asia Pacific-centered biotech CRO today announced the acquisition of CBR International, a global product development, clinical oversight and strategic regulatory operations group.CBR was founded in 2002 as a consultancy company focused on assisting biotechnology and pharma companies navigate FDA requirements from early-stage development through to approval. CBR adds a group of experts to Novotech to provide US and global regulatory, scientific, quality, and clinical development services. CBR's specific regulatory expertise and services include long-range Regulatory Strategy and Writing, FDA Representation, eSubmissions, and Scientific Affairs to support requirements for cGMP commercial product development.The acquisition will further strengthen Novotech's capabilities in regulatory strategy and US FDA interactions and submissions including IND, IDE, NDA, BLA, Fast-Track, Break-through, and Orphan Drug Applications.Novotech CEO Dr. John Moller said: "CBR will provide decades of FDA regulatory experience for our biotech clients. They have experience across all product types and are highly regarded for their IND expertise having managed approximately 80 INDs through all phases of development. This acquisition, together with Novotech's existing regulatory affairs capability, creates a large global group of experts in toxicology, drug development, and global regulatory submissions support. This regulatory expertise benefits our US, European, and Asia Pacific biotech clients as they progress through the US clinical environment and navigate often complex FDA requirements."CEO and Founder of CBR, Dr. Jeanne Novak said: "We are extremely pleased to be joining a company the size and calibre of Novotech which brings global demand for our regulatory expertise. The US is an important region for global biotech and pharma companies as part of their clinical program development. We have the experience and track-record of directly supporting US approvals for over 10 programs. Navigating novel product development and achieving multiple approvals has built our expertise to support the complex development needs of clients worldwide which will now support Novotech clients. We look forward to working with Novotech clients to support their drug development programs in the US and globally. We are excited to continue working with our clients and bringing Novotech expanded services to our colleagues."Novotech has decades of biotech drug development experience, exceptional site and investigator relationships, access to vast patient populations, and a project management approach focused on problem-solving, ownership and flexibility. Consistent investment in advanced training and technology combines to deliver a specialist full-service biotech CRO solution.Novotech has recently been recognised with significant CRO awards including the Asia-Pacific Biotech CRO of the Year by Frost & Sullivan, benchmarked as a top 10 CRO among the world's leading CROs, a finalist in the prestigious Scrip awards, and has just been awarded the Gene & Cell Therapy Excellence Award. In Asia Pacific Novotech has more than 50 Leading Site Partnership agreements with major medical research institutions which delivers exclusive benefits for sponsors.About NovotechNovotech is the leading Asia-Pacific centered biotech CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. Novotech is well-positioned to serve biotech clients conducting clinical trials in Asia-Pacific the US, and Europe. For more information visit https://novotech-cro.com/contactMedia ContactDavid JamesE: communications@novotech-cro.comAU: +61 2 8218 2144USA: +1 415 951 3228Asia: +65 3159 3427 Copyright 2023 ACN Newswire. All rights reserved. (via SEAPRWire)
More
HighTide Therapeutics Raises $107 Million in Series C/C+ Financing to Advance Innovative Pipeline and Business Collaborations ACN Newswire

HighTide Therapeutics Raises $107 Million in Series C/C+ Financing to Advance Innovative Pipeline and Business Collaborations

January 5, 2023
ROCKVILLE, MD and SHENZHEN, CHINA, Jan 5, 2023 - (ACN Newswire via SEAPRWire.com) - HighTide Therapeutics Inc. ("HighTide"), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced the closing of a $107 million Series C/C+ financing led by the TCM Healthcare Fund of Guangdong, managed by China Development Bank Capital. Other investors included Yuexiu Fund and Yuthai Fund. Proceeds of the financing will be used to advance multiple global development programs, including mid-to-late-stage clinical trials, and the commercialization and business development of the company's robust pipeline. HighTide's lead candidate HTD1801, is a novel multifunctional molecule, being developed for the treatment of patients suffering from complex metabolic and digestive diseases. HighTide has successfully completed multiple clinical trials of HTD1801 and continues to advance its global development programs as follows:-- A Phase 2 clinical study in type 2 diabetes (T2DM) is near completion;-- A Phase 2b clinical study in nonalcoholic steatohepatitis (NASH) has been initiated; and -- A successful End-of-Phase 2 (EOP2) meeting was held with the U.S. Food and Drug Administration (FDA) based on the positive findings from the Phase 2 clinical study in primary sclerosing cholangitis (PSC)."After completing a successful $60 million Series B+ round at the end of 2020, we are thrilled to have well-recognized investors participate in our C/C+ round. We are grateful that our investors have such strong confidence in HighTide's team, the commercial value of our pipeline, and future development prospects," said Liping Liu, Ph.D., founder and Chief Executive Officer of HighTide. "The Series C/C+ financing is a significant milestone for HighTide. It will enable us to move aggressively to accelerate the clinical and commercial development of our innovative pipeline and external business collaborations."About HighTide TherapeuticsHighTide is a globally integrated clinical-stage biopharmaceutical company focusing on the discovery and development of novel multifunctional therapies for metabolic and digestive diseases with significant unmet medical needs. The company's lead drug candidate, HTD1801, is a first-in-class new molecular entity, currently in clinical development for the treatment of type 2 diabetes (T2DM), nonalcoholic steatohepatitis (NASH), severe hypertriglyceridemia (SHTG), and primary sclerosing cholangitis (PSC). The U.S. Food and Drug Administration (FDA) granted Fast Track designation to HTD1801 for both NASH and PSC, as well as Orphan Drug designation for PSC. In China, HTD1801 has been included in the National Major New Drug Innovation Program. For more information, please visit www.hightidetx.com.Contacts:InvestorsNadia Gaoir@hightidetx.com+86-134-8219-0265MediaKarl Schmiederkarl@messaginglab.com+1-646-515-3392 Copyright 2023 ACN Newswire. All rights reserved. (via SEAPRWire)
More
The best of the best real estate developers, projects prevail at 17th PropertyGuru Asia Property Awards Grand Final ACN Newswire

The best of the best real estate developers, projects prevail at 17th PropertyGuru Asia Property Awards Grand Final

December 10, 2022
BANGKOK, THAILAND, Dec 10, 2022 - (ACN Newswire via SEAPRWire.com) - PropertyGuru Group (NYSE: PGRU), Southeast Asia's leading property technology company, today announced the regional winners representing the Best in Asia at the 17th Annual PropertyGuru Asia Property Awards Grand Final, presented by Kohler and supported by Leading Real Estate Companies of the World.-- New World Development Company Limited is hailed Best Developer (Asia) in one of two regional wins for companies from China (Hong Kong and Macau)-- Companies from Thailand and the Philippines each garner seven regional wins -- Candra Ciputra, CEO of Ciputra Group and president director of PT Ciputra Development Tbk, receives the PropertyGuru Icon awardAlso known as the finale of the 2022 PropertyGuru Asia Property Awards series, the Grand Final was presented in 48 categories at The Athenee Hotel, a Luxury Collection Hotel, Bangkok. New World Development Company Limited garnered the award of Best Developer (Asia), representing China (Hong Kong and Macau). Along with the design practice Lead8, the company also received the Best Mega Mixed Use Development (Asia) award for 11 SKIES.Representing Mainland China, Lead8 additionally won the Best Retail Architectural Design (Asia) award for Shougang Park Urban Weaving District. Benoy Limited won Best Mixed Use Architectural Design (Asia) for CRL MixC Qianhai in another regional win for Mainland China. The Philippines garnered seven regional wins, led by the Best Industrial Developer (Asia) title for Aboitiz InfraCapital Economic Estates and Best Lifestyle Developer (Asia) title for Global-Estate Resorts, Inc. (GERI). Aboitiz InfraCapital Economic Estates also won the honours of Best Industrial Development (Asia) and Best Green Development (Asia) for LIMA Estate. AppleOne Mactan, Inc. also won Best Branded Residential Development (Asia) for The Residences at Sheraton Cebu Mactan Resort while Cebu Landmasters, Inc. won Best Hospitality Architectural Design (Asia) for Sofitel Cebu City. Arquitectonica was honoured with the Best Office Architectural Design (Asia) award for Mega Tower. Thailand also gained seven regional wins, including the Best Landmark Mixed Use Development (Asia) award for One Bangkok by Frasers Property Holdings (Thailand) Co., Ltd. (FPHT). Magnolia Quality Development Corporation Limited won both the Best Condo Development (Asia) and Best Health and Wellness Development (Asia) awards for The Aspen Tree at The Forestias. PMT Property Co., Ltd. earned the titles of Best Condo Interior Design (Asia) and Best Condo Landscape Architectural Design (Asia) for 125 Sathorn. Lake Legend Bangna-Suvarnabhumi by Hongkong Land and Property Perfect PCL was named Best Waterfront Housing/Landed Development (Asia) while Jaytiya 2 Private Pool Villas Residence by Jaytiya Property Co., Ltd. won Best Housing/Landed Landscape Architectural Design (Asia). Singapore scored six regional wins at the Grand Final. GuocoLand was named Best Luxury Developer (Asia) and Best Sustainable Developer (Asia) while UOL Group Limited was named Best Hospitality Developer (Asia). UOL Group Limited also won Best Hotel Development (Asia) for Pan Pacific Orchard. Park Nova by Shun Tak Holdings gained the Best Condo Architectural Design (Asia) title while Artyzen Singapore by Artyzen Hospitality Group won Best Hospitality Interior Design (Asia). Indonesia was also represented with six regional wins that include the Best Township Development (Asia) award for Kota Baru Parahyangan by PT. Belaputera Intiland and Best Township Masterplan Design (Asia) award for PIK2 Sedayu Indo City by Agung Sedayu Group & Salim Group. Autograph Tower at Thamrin Nine Complex by PT Putragaya Wahana, a member of Galeon Group, won Best Office Development (Asia) while LRT City Jatibening by KSO PT Adhi Commuter Properti Tbk. & PT Urban Jakarta Propertindo Tbk. won Best Connectivity Condo Development (Asia). Metland Cibitung by PT Fajarputera Dinasti, a subsidiary of PT Metropolitan Land Tbk., won Best Connectivity Housing/Landed Development (Asia) while LOGOS Cikarang Logistics Park by LOGOS Indonesia was named Best Green Industrial Development (Asia).Australia scored five regional wins, including the Best Boutique Developer (Asia) title for Spacious Group. SPG Land won both the Best Smart Building Development (Asia) and Best Integrated Work From Home Development (Asia) titles for Paradiso Place. Dare Property Group won Best Eco Friendly Commercial Development (Asia) for Zero Gipps and Mayrin Group won Best Housing/Landed Architectural Design (Asia) for The Archwood Residences.Vietnam scored four regional wins, including the Best Mixed Use Developer (Asia) title for Keppel Land. Sycamore by CapitaLand Development (Vietnam) won the Best Housing/Landed Development (Asia) and Best Eco Friendly Housing/Landed Development (Asia) awards. Artisan Park by Gamuda Land was named Best Retail Development (Asia). From Greater Niseko, Andaru Collection Niseko by Blue Waves Group clinched both Best Completed Housing/Landed Development (Asia) and Best Housing/Landed Interior Design (Asia) awards. HakuVillas by H2 Group won the Best Completed Condo Development (Asia) award. Cambodia and Malaysia each earned two regional wins. The Best Breakthrough Developer (Asia) award went to Kambujaya Development Co., Ltd, with the Best Waterfront Condo Development (Asia) title going to Vue Aston by The Peninsula Capital Co., Ltd. KL Wellness City by KL Wellness City Sdn Bhd was named Best Mixed Use Development (Asia), with Infinity8 Reserve JBCC by Infinity Group winning Best Co-Working Space (Asia). India was also represented at the Grand Final with Embassy REIT winning Best Commercial Landscape Architectural Design (Asia) for Embassy TechVillage - Central Garden. Candra Ciputra, CEO of Ciputra Group and president director of PT Ciputra Development Tbk, received the PropertyGuru Icon Award. Ciputra, previously named the Indonesia Real Estate Personality of the Year in 2015, received the award for a lifetime of real estate achievements covering developments in more than 40 cities across the archipelago. The regional winners at the Grand Final were selected from the elite pool of country winners from PropertyGuru Asia Property Awards' series of celebrations this year in Singapore, Malaysia, Indonesia, Thailand, Vietnam, Cambodia, the Philippines, Mainland China, Hong Kong, Macau, Greater Niseko (Japan), India, and Australia.Hari V Krishnan, CEO and managing director of PropertyGuru Group, said: "The Awards remain among our widest-reaching enterprise solutions, having expanded over the years to represent some of the world's most dynamic property markets from Southeast Asia to Australia. With these award-winning developers and designers as benchmarks, we hope to guide property seekers towards finding, financing and owning the right properties. In this, the 17th edition of the PropertyGuru Asia Property Awards Grand Final, we elevate not only the region's dream homes but also its finest, most sustainable live-work-play developments, workspaces, retail hubs, hotels, resorts, and industrial parks, among others, to an international platform. Whether you're seeking, selling or building property, we will see you home."Jules Kay, general manager of PropertyGuru Asia Property Awards and Events, said: "The winners of the PropertyGuru Asia Property Awards Grand Final aptly represent the diversity, progress, and resilience of their respective property markets. With projects ranging from boutique residential developments to vast integrated districts, these award-winning developments offer an impressive snapshot of what the Best in Asia looks like. Whether celebrated onstage at our gala events, or presented to the world online, these awardees shine bright as the Gold Standard of Asian real estate, keeping true to our vision of building the region's Property Trust Platform. To all the winners announced at our regional Grand Final - we celebrate your success. Congratulations."The latest edition of the Grand Final marked the full return of the black-tie gala dinner and awards presentation, following a successful virtual gala edition in 2021. The 2022 Grand Final was streamed live on AsiaPropertyAwards.com as well as the programme's official Facebook and YouTube channels. The list of winners at the Grand Final was selected by an independent jury consisting of head judges of participating markets in the Awards: Thien Duong, chairperson of the Grand Final and general director, Group GSA (Vietnam); Amit Khanna, managing director, Phoenix Advisers (India); Bill Barnett, founder and managing director, C9 Hotelworks (Greater Niseko); Cyndy Tan Jarabata, president of TAJARA Leisure & Hospitality Group Inc. (Philippines); Dato' Sr. Lau Wai Seang, president, Royal Institution of Surveyors Malaysia (RISM): 2017-2018 (Malaysia); Kristin Thorsteins, head of partnership growth for APAC at IWG PLC (Singapore); Lui Violanti, regional manager for Western Australia, Inhabit Group (Australia); Paul Tse, president, board of directors, Macao Association of Building Contractors and Developers (Mainland China, Hong Kong and Macau); Sorn Seap, executive vice president, Cambodian Valuers and Estate Agents Association (Cambodia); Suphin Mechuchep, chairperson, JLL Thailand (Thailand); and Vivin Harsanto, senior director and head of advisory, JLL Indonesia (Indonesia).HLB, the leading international accounting and advisory firm, upheld fairness, transparency and credibility throughout all points of the selection process, under the leadership of Paul Ashburn, HLB International Real Estate Group.Since it was established in Thailand in 2005, the PropertyGuru Asia Property Awards programme has expanded over the years to 18 property markets. Through its series of in-person and virtual gala celebrations, the PropertyGuru Asia Property Awards programme has provided an international platform for excellent real estate developers, architects, and interior designers across Asia Pacific. The programme therefore connects awardees to a wide pool of investors, consumers, and agents, as well as the diaspora, throughout the region and beyond. Organised by PropertyGuru Group (NYSE: PGRU), the 17th PropertyGuru Asia Property Awards Grand Final is supported by platinum sponsor Kohler; gold sponsor Leading Real Estate Companies of the World; official portal partner PropertyGuru; official channel partner History; official magazine Property Report by PropertyGuru; official PR partner Artemis Associates; media partners BusinessWorld, Construction & Property, d+a Magazine, Daily FT, Deluxe Magazine, Discover Pattaya, Esquire PH, Hot Magazine, Housing.com, Kompas, Kopiandpropetry.com, Luxuo, Manila Bulletin, Mingtiandi, Palace, Pattaya Trader, Penang Property Talk, People Asia Magazine, PhilStar PropertyReport PH, Powderlife, Real Estate News PH, Real Living, Rem, Robb Report, Southeast Asia Globe, Suara Indonesia, The Grid, The Hindu, The Manila Times, Think of Living, Top 10 of Malaysia, Vietnam Heritage, WhenInManila.com, Yacht Style, and Your Investment Property; official ESG partner Baan Dek Foundation; official charity partner Liter of Light; supporting partners IFC - Building Resilience Index, IFC - Excellence in Design for Greater Efficiencies, and REHDA Institute; supporting associations EuroCham Cambodia, Global Design Awards Lab, Green Building Consulting & Engineering, Niseko Tourism, Singapore Estate Agents Association, and Singapore Green Building Council; and official supervisor HLB. For more information, email awards@propertyguru.com or visit the official website: AsiaPropertyAwards.com.LIST OF REGIONAL AND COUNTRY WINNERS 17th PropertyGuru Asia Property Awards Grand FinalDEVELOPER AWARDSBest Developer (Asia)Agung Sedayu Group - IndonesiaAuriton Group - AustraliaNew World Development Company Limited - China - Hong Kong and Macau (REGIONAL WINNER)Prince Real Estate Group - CambodiaRobinsons Land - PhilippinesUOL Group Limited - SingaporeBest Luxury Developer (Asia)GuocoLand - Singapore (REGIONAL WINNER)SonKim Land Corporation - Vietnam Best Industrial Developer (Asia)Aboitiz InfraCapital Economic Estates - Philippines (REGIONAL WINNER)PT LOGOS SEA Indonesia - IndonesiaBest Mixed Use Developer (Asia)GuocoLand - SingaporeKeppel Land - Vietnam (REGIONAL WINNER)Megaworld Corporation - PhilippinesPrince Real Estate Group - CambodiaBest Hospitality Developer (Asia)Megaworld Corporation - PhilippinesUOL Group Limited - Singapore (REGIONAL WINNER)Best Lifestyle Developer (Asia)Aurum Land (Private) Limited - SingaporeCasagrand Builder Pvt. Ltd. - IndiaGlobal-Estate Resorts,Inc. (GERI) - Philippines (REGIONAL WINNER)Best Sustainable Developer (Asia)GuocoLand - Singapore (REGIONAL WINNER)PT. Bumi Serpong Damai - IndonesiaPT LOGOS SEA Indonesia - IndonesiaBest Boutique Developer (Asia)Aurum Land (Private) Limited - SingaporePT. Bumi Parama Wisesa (NavaPark) Hongkong Land & Sinar Mas Land Joint Venture - IndonesiaSpacious Group - Australia (REGIONAL WINNER)Best Breakthrough Developer (Asia)Kambujaya Development Co., Ltd - Cambodia (REGIONAL WINNER)DEVELOPMENT AWARDSBest Township Development (Asia)Bridgetowne Destination Estate by Robinsons Land - PhilippinesCorrectio by PT. Jababeka Tbk - IndonesiaKota Baru Parahyangan by PT. Belaputera Intiland - Indonesia (REGIONAL WINNER)Meyhomes Capital Phu Quoc by Tan A Dai Thanh - Meyland - VietnamBest Mega Mixed Use Development (Asia)11 SKIES by Lead8 & New World Development Company Limited - China - Hong Kong and Macau (REGIONAL WINNER)Best Landmark Mixed Use Development (Asia)One Bangkok by Frasers Property Holdings (Thailand) Co., Ltd. (FPHT) - Thailand (REGIONAL WINNER)Best Mixed Use Development (Asia)Baker Circle by Henderson Land Development Company Limited - China - Hong Kong and MacauBalfour Place by Thirdi Group - AustraliaEmbassy Manyata Front Parcel Development by Embassy REIT - IndiaHeartland 66 by Hang Lung Properties - Mainland ChinaKL Wellness City by KL Wellness City Sdn Bhd - Malaysia (REGIONAL WINNER)Melbourne Square by OSK Property - AustraliaPrince International Plaza by Prince Real Estate Group - CambodiaThamrin Nine Complex by PT Putragaya Wahana, a member of Galeon Group - IndonesiaBest Industrial Development (Asia)FoodFab @ Mandai by Mandai 7 JV Pte Ltd - SingaporeGIIC @ Kota Deltamas by Sinar Mas Land & Sojitz Corporation - IndonesiaLIMA Estate by Aboitiz InfraCapital Economic Estates - Philippines (REGIONAL WINNER)Best Hotel Development (Asia)Pan Pacific Orchard by UOL Group Limited - Singapore (REGIONAL WINNER)Park Hyatt Niseko Hanazono and Hanazono Resort Niseko by Nihon Harmony Resorts KK and PCPD - Greater NisekoBest Retail Development (Asia)Artisan Park by Gamuda Land - Vietnam (REGIONAL WINNER)Batavia PIK by Agung Sedayu Group & Salim Group, curated by Amantara - IndonesiaBest Office Development (Asia)888 Lai Chi Kok Road (NCB Innovation Centre) by New World Development Company Limited - China - Hong Kong and MacauAutograph Tower at Thamrin Nine Complex by PT Putragaya Wahana, a member of Galeon Group - Indonesia (REGIONAL WINNER)Cloud Land, Hangzhou by Greentown China Holdings Limited - Mainland ChinaFrasers Tower by Frasers Property Singapore - SingaporeHudson & Ganges Office Towers, Embassy TechZone by Embassy REIT - IndiaKnowledge Hub @Digital Hub by Sinar Mas Land - IndonesiaOne Bangkok Office Tower 4 by Frasers Property Holdings (Thailand) Co., Ltd. (FPHT) - ThailandBest Branded Residential Development (Asia)The Residences at Sheraton Cebu Mactan Resort by AppleOne Mactan, Inc. - Philippines (REGIONAL WINNER)Best Condo Development (Asia)Forbes Residences, Applecross by Mustera Property Group Ltd - AustraliaHinode Hills by Niseko Village - Greater NisekoKincang Egrets Waves 3.0 Residential by LYCS Architecture - Mainland ChinaLe Parc at Thamrin Nine Complex by PT Putragaya Wahana, a member of Galeon Group - IndonesiaMeyer Mansion by GuocoLand - SingaporeOne Innovale by Henderson Land Development Company Limited - China - Hong Kong and MacauParc3 by Eupe Corporation Berhad - MalaysiaPiramal Aranya by Piramal Realty - IndiaThe Aspen Tree at The Forestias by Magnolia Quality Development Corporation Limited - Thailand (REGIONAL WINNER)The Seasons Residences by Sunshine Fort North Bonifacio Realty Development Corporation - PhilippinesVue Aston by The Peninsula Capital Co., Ltd. - CambodiaBest Waterfront Condo Development (Asia)Costa Mira Beachtown Mactan by Cebu Landmasters, Inc. - PhilippinesLee Nam Road 66 by Logan Group Company Limited & KWG Group Holdings - China - Hong Kong and MacauMeyer Mansion by GuocoLand - SingaporeParadiso Place by SPG Land - AustraliaSunteck Beach Residences (SBR) by Sunteck Realty Limited - IndiaVue Aston by The Peninsula Capital Co., Ltd. - Cambodia (REGIONAL WINNER)Best Connectivity Condo Development (Asia)LRT City Jatibening by KSO PT Adhi Commuter Properti Tbk. & PT Urban Jakarta Propertindo Tbk. - Indonesia (REGIONAL WINNER)Best Completed Condo Development (Asia)HakuVillas by H2 Group - Greater Niseko (REGIONAL WINNER)Best Health and Wellness Development (Asia)Forbes Estates Lipa by Robinsons Land - PhilippinesMark Moran Warrawee by Mark Moran Group - AustraliaThe Aspen Tree at The Forestias by Magnolia Quality Development Corporation Limited - Thailand (REGIONAL WINNER)Best Smart Building Development (Asia)Paradiso Place by SPG Land - Australia (REGIONAL WINNER)Best Housing/Landed Development (Asia)Belgravia Ace by Fairview Developments Pte Ltd (a unit of Tong Eng Group) - SingaporeEnchante Residence @BSD City by Sinar Mas Land - IndonesiaGuangzhou Nansha Amber Living by Zhuhai Huafa Properties Co., Ltd. - Mainland ChinaSycamore by CapitaLand Development (Vietnam) - Vietnam (REGIONAL WINNER)The Archwood Residences by Mayrin Group - AustraliaBest Waterfront Housing/Landed Development (Asia)Lake Legend Bangna-Suvarnabhumi by Hongkong Land and Property Perfect PCL - Thailand (REGIONAL WINNER)The Residences III at The Glades, Putra Heights by Sime Darby Property - MalaysiaBest Connectivity Housing/Landed Development (Asia)Metland Cibitung by PT Fajarputera Dinasti a subsidiary of PT Metropolitan Land Tbk. - Indonesia (REGIONAL WINNER)Best Completed Housing/Landed Development (Asia)Andaru Collection Niseko by Blue Waves Group - Greater Niseko (REGIONAL WINNER)Best Integrated Work From Home Development (Asia)Paradiso Place by SPG Land - Australia (REGIONAL WINNER)Pisonia Ville by UDA Holdings Berhad - MalaysiaBest Green Development (Asia)LIMA Estate by Aboitiz InfraCapital Economic Estates - Philippines (REGIONAL WINNER)Best Green Industrial Development (Asia)LOGOS Cikarang Logistics Park by LOGOS Indonesia - Indonesia (REGIONAL WINNER)Best Eco Friendly Housing/Landed Development (Asia)Sycamore by CapitaLand Development (Vietnam) - Vietnam (REGIONAL WINNER)Best Eco Friendly Commercial Development (Asia)Site of the Future - Acienda Silang by Pilipinas Shell Petroleum Corporation - PhilippinesZero Gipps by Dare Property Group - Australia (REGIONAL WINNER)DESIGN AWARDSBest Township Masterplan Design (Asia)Bridgetowne Destination Estate by Robinsons Land - PhilippinesPIK2 Sedayu Indo City by Agung Sedayu Group & Salim Group - Indonesia (REGIONAL WINNER)Best Mixed Use Architectural Design (Asia)11 SKIES by Lead8 - China - Hong Kong and MacauCRL MixC Qianhai by Benoy Limited - Mainland China (REGIONAL WINNER)Yoho Treasure Island Resorts World Hotel, Macau by Huarchi Global Design Corporation Ltd & Treasure Island Entertainment Company Ltd - China - Hong Kong and MacauBest Condo Architectural Design (Asia)AMO Residence by UOL Group Limited, Singapore Land Group Limited, Kheng Leong Company - SingaporeMeyer Mansion by GuocoLand - SingaporeOne East @ Damansara by CK East Group - MalaysiaParadiso Place by SPG Land - AustraliaPark Nova by Shun Tak Holdings - Singapore (REGIONAL WINNER)Railway Leisure Town by HZS Design (Shanghai) Ltd. - Mainland ChinaReference Sathorn - Wongwianyai by SC Asset - ThailandThe Commodore by JBE Holdings Pte Ltd - SingaporeThe East Village at DGT by Cebu Landmasters, Inc. - PhilippinesWaterfall Heights, Patong Bay (Phuket) by PropertyStore Thailand Co., Ltd. - ThailandBest Housing/Landed Architectural Design (Asia)Andaru Collection Niseko by Blue Waves Group - Greater NisekoLake Legend Bangna-Suvarnabhumi by Hongkong Land and Property Perfect PCL - ThailandMazenta Residence by PT Cipta Harmoni Lestari - IndonesiaSeri Austin Heights by Aksi Sepakat Sdn Bhd - MalaysiaThe Archwood Residences by Mayrin Group - Australia (REGIONAL WINNER)The Valley by Botanica Luxury Villas - ThailandVenue ID Motorway Rama 9 by SC Asset - ThailandBest Hospitality Architectural Design (Asia)Artyzen Singapore by Artyzen Hospitality Group - SingaporeShiguchi by Kookan - Greater NisekoSofitel Cebu City by Cebu Landmasters, Inc. - Philippines (REGIONAL WINNER)Best Retail Architectural Design (Asia)Pantjoran PIK by Agung Sedayu Group & Salim Group, curated by Amantara - IndonesiaShougang Park Urban Weaving District by Lead8 - Mainland China (REGIONAL WINNER)Best Office Architectural Design (Asia)Embassy Oxygen, Tower-1 by Embassy REIT - IndiaMega Tower by Arquitectonica - Philippines (REGIONAL WINNER)One Bedford Place by Lofter Group Limited - China - Hong Kong and MacauBest Condo Interior Design (Asia)125 Sathorn by PMT Property Co., Ltd. - Thailand (REGIONAL WINNER)Liv @ MB by Bukit Sembawang Estates Limited - SingaporeOrchard Sophia by Orchard Sophia Pte Ltd - SingaporeParadiso Place by SPG Land - AustraliaPerfect Ten by Property Enterprises Development (Singapore) Pte Ltd - SingaporeThe Commodore by JBE Holdings Pte Ltd - SingaporeThe Residences at Sheraton Cebu Mactan Resort by AppleOne Mactan, Inc. - PhilippinesBest Housing/Landed Interior Design (Asia)Andaru Collection Niseko by Blue Waves Group - Greater Niseko (REGIONAL WINNER)Kambujaya Residences by Kambujaya Development Co., Ltd - CambodiaMazenta Residence by PT Cipta Harmoni Lestari - IndonesiaThe Archwood Residences by Mayrin Group - AustraliaBest Hospitality Interior Design (Asia)Artyzen Singapore by Artyzen Hospitality Group - Singapore (REGIONAL WINNER)Sheraton Cebu Mactan Resort by AppleOne Mactan, Inc. - Philippines Shiguchi by Kookan - Greater NisekoBest Condo Landscape Architectural Design (Asia)125 Sathorn by PMT Property Co., Ltd. - Thailand (REGIONAL WINNER)AMO Residence by UOL Group Limited, Singapore Land Group Limited, Kheng Leong Company - SingaporePark Nova by Shun Tak Holdings - SingaporeWaterfall Heights, Patong Bay (Phuket) by PropertyStore Thailand Co., Ltd. - ThailandBest Housing/Landed Landscape Architectural Design (Asia)Jaytiya 2 Private Pool Villas Residence by Jaytiya Property Co., Ltd. - Thailand (REGIONAL WINNER)Meysenses Lucia Bay Bai Lu by Tan A Dai Thanh - Meyland - VietnamBest Commercial Landscape Architectural Design (Asia)Embassy TechVillage - Central Garden by Embassy REIT - India (REGIONAL WINNER)Best Co-Working Space (Asia)Infinity8 Reserve JBCC by Infinity Group - Malaysia (REGIONAL WINNER)work.able Exxa-Zeta Center by Robinsons Land - PhilippinesPUBLISHER'S CHOICEPropertyGuru Icon AwardWINNER: Candra CiputraCEO, Ciputra GroupPresident Director, PT Ciputra Development TbkNOTE: Use of the PropertyGuru Asia Property Awards logo is limited to the publication of this article only.PROPERTYGURU CONTACTS:General Enquiries:Richard Allan AquinoHead of Brand & Marketing ServicesM: +66 92 954 4154E: allan@propertyguru.com Sponsorships:Kanittha SrithongsukRegional Manager, Awards SponsorshipM: +66 93 293 9794E: kanittha@propertyguru.com Media & Partnerships:Nate DacuaMedia Relations & Marketing Services ManagerM: +66 92 701 2510E: nate@propertyguru.com Sales & Nominations:Udomluk SuwanSales DirectorM: +66 87 699 4433E: may@propertyguru.comABOUT PROPERTYGURU ASIA PROPERTY AWARDS:PropertyGuru's Asia Property Awards, established in 2005, are the region's most exclusive and prestigious real estate awards programme. The Asia Property Awards are recognised as the ultimate hallmark of excellence in the Asian property sector. Boasting an independent panel of industry experts and trusted supervisors, the Awards have an unparalleled reputation for being credible, ethical, fair and transparent.In 2022, the Awards series is open to more than a dozen key property markets around the region. The exciting gala events welcome senior industry leaders and top media, as well as reach property agents and consumers via live streaming. Recognising excellence within each Asian market with a variety of categories, including green and sustainable development, each local awards programme will culminate in the PropertyGuru Asia Property Awards Grand Final, which takes place after the PropertyGuru Asia Real Estate Summit during 'PropertyGuru Week' in December 2022.For more information, please visit AsiaPropertyAwards.comABOUT PROPERTYGURU GROUP:PropertyGuru is Southeast Asia's leading1 PropTech company, and the preferred destination for over 44 million property seekers7 (https://www.propertygurugroup.com/newsroom/propertyguru-reports-third-quarter-2022-results/#news_icon) to find their dream home, every month. PropertyGuru empowers property seekers with more than 3.5 million real estate listings8 (https://www.propertygurugroup.com/newsroom/propertyguru-reports-third-quarter-2022-results/#news_icon), in-depth insights, and solutions that enable them to make confident property decisions across Singapore, Malaysia, Thailand, Indonesia, and Vietnam.PropertyGuru.com.sg was launched in Singapore in 2007 and since then PropertyGuru Group has made the property journey a transparent one for property seekers in Southeast Asia. In the last 15 years, PropertyGuru has grown into a high-growth PropTech company with a robust portfolio of leading property marketplaces across its core markets; award-winning mobile apps; mortgage marketplace, PropertyGuru Finance (https://www.propertyguru.com.sg/mortgage/home-loan); and a host of enterprise solutions now under PropertyGuru For Business (https://www.propertyguruforbusiness.com/), including a high-quality developer sales enablement platform, FastKey (https://www.propertyguruforbusiness.com/fastkey), DataSense (https://www.propertyguruforbusiness.com/datasense), ValueNet (https://www.propertyguruforbusiness.com/real-estate-valuers), Awards (https://www.asiapropertyawards.com/en/), events and publications across Asia.For more information, please visit: PropertyGuruGroup.com; PropertyGuru Group on LinkedIn (https://www.linkedin.com/company/propertyguru).1. Based on SimilarWeb data between April 2022 and September 2022.2. The third quarter and first nine months ended September 30, 2022 includes results of the iProperty Malaysia and thinkofliving businesses which were acquired on August 3, 2021. 3. Included in the S$13.2 million of adjustments between net loss and Adjusted EBITDA in the third quarter of 2022 was a S$4.9 million depreciation and amortization expense.4. Included in the S$8.2 million of adjustments between net loss and Adjusted EBITDA in the third quarter of 2021 were a S$3.9 million depreciation and amortization expense and a S$3.0 million net finance expense.5. Based on SimilarWeb data between April 2022 and September 2022.6. Does not include impact of Sendhelper acquisition in October 2022.7. Based on Google Analytics data between April 2022 and September 2022.8. Based on data between April 2022 and September 2022. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Japan, United Kingdom and Italy Formally Announce Joint Development of a Next-Generation Fighter JCN Newswire

Japan, United Kingdom and Italy Formally Announce Joint Development of a Next-Generation Fighter

December 9, 2022
TOKYO, Dec 9, 2022 - (JCN Newswire via SEAPRWire.com) - The Government of Japan today announced the joint development of the country's next-generation fighter together with partners in the U.K. and Italy.In recent years, Mitsubishi Heavy Industries, Ltd. (MHI) has developed cutting-edge technologies for fighter through diverse research initiatives, including the "X-2," an advanced technology demonstrator jet. Since October 2020, when a contract was concluded with the Ministry of Defense on development of the future fighter aircraft (F-X), MHI has conducted a conceptual design and other development-related work. Simultaneously, MHI has been looking into the feasibility of collaboration with the U.K. and Italian defense industries under the leadership of the governments of the three nations.Following the formal announcement of the joint development by the three nations' governments, the development program will now go forward concurrently in Japan, the U.K. and Italy. MHI will work closely with the government authorities and corporate partners from all three nations, in order to develop the next-generation fighter, pooling our respective cutting-edge technologies and expertise.This international collaborative project, with the broad participation of Japan's defense companies, will foster innovation in the country's industrial sector such as digital transformation, as well as the development of human resources in the field of science and technology. Through its development of the next-generation fighter, MHI will strengthen the country's defense industrial base as a whole and continue making significant contributions to Japan's national security.About MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world's leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)
More
Novotech Awarded the Asia Pacific CRO of the Year 2022 for Best Practices in Clinical Trials ACN Newswire

Novotech Awarded the Asia Pacific CRO of the Year 2022 for Best Practices in Clinical Trials

December 6, 2022
SYDNEY, AU, Dec 6, 2022 - (ACN Newswire via SEAPRWire.com) - Novotech, the leading Asia Pacific biotech specialist CRO, has been awarded the Frost & Sullivan Company of the Year Award 2022 for Best Practices in the Asia-Pacific contract research organization industry. Novotech has been a recipient of the Frost & Sullivan Asia Pacific Best Practices awards since 2006.Frost & Sullivan identifies companies that consistently develop growth strategies based on a visionary understanding of the future, and effectively address new challenges and opportunities.Frost & Sullivan said: "Our approach involves the deployment of best practices and strategic analytics across a value chain. Against this backdrop, Frost & Sullivan recognizes Novotech for its valuable achievement. Novotech addresses the global drug development market's unmet needs with a strong leadership focus that incorporates client-centric strategies with best-practice implementation. From feasibility assessments to regulatory submission support, data management, medical monitoring, and project management, the company provides a 360-degree approach to drug development for its biotech clients."In response to the Company of the Year Award announcement, Novotech CEO Dr. John Moller said this award is a credit to our entire global team which has decades of biotech drug development experience."Every day our team supports biotech companies in their drug development programs with unparalleled regulatory knowledge, vast site and investigator networks, technology-driven clinical data management, and a project management approach focused on problem-solving, ownership, and flexibility. Our global clients benefit from access to our expert teams in Asia Pacific, which is the fastest-growing clinical trial region, due to its vast patient populations and sophisticated medical research infrastructure. Our consistent investment in advanced training and technology systems combine to deliver a specialist full-service biotech CRO solution."Novotech regularly produces expert reports on East-West strategies. A new publication is now available for international biotechs considering China for their clinical research, as well as China biotechs conducting research in China, and the relevant processes required for global regulatory approvals. The report details regulatory requirements for biotechs including NDA and IND processes as well as ex-US research guidance for a successful US FDA approval pathway. Novotech can provide the relevant regulatory knowledge and drug development pathways specifically designed to support the US FDA approval process, avoiding delays and additional costs.Download whitepaper here https://novotech-cro.com/whitepapers/china-biotech-landscape-opportunities-china-and-path-usfda-approvalNovotech has also recently been benchmarked as a top 10 CRO among the world's leading CROs, is a finalist in the prestigious Scrip awards, and has just been awarded the Gene & Cell Therapy Excellence Award. In Asia Pacific Novotech has more than 50 Leading Site Partnership agreements with major medical research institutions delivering exclusive benefits for sponsors.About Novotech Novotech is the leading Asia Pacific biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas. Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit https://novotech-cro.com/contactMedia ContactDavid JamesE: communications@novotech-cro.comAU: +61 2 8218 2144 USA: +1 415 951 3228Asia: +65 3159 3427 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
IBO Technology Announces 2022 Interim Results ACN Newswire

IBO Technology Announces 2022 Interim Results

November 30, 2022
HONG KONG, Nov 30, 2022 - (ACN Newswire via SEAPRWire.com) - IBO Technology Company Limited ("IBO Technology", or the "Company", together with its subsidiaries, the "Group"; Stock Code: 2708.HK) is pleased to announce its unaudited interim results for the six months ended 30 September 2022 (the "Period"). To promote the business development of Information Technology Application Innovation Information ("ITAI") and seize the industry golden opportunities, the Group cooperated with the People's Government of Fucheng District, Mianyang City, Sichuan Province ("Fucheng District People's Government") during the Period to develop an intelligent manufacturing industrial park project.During the Period, the demand for ITAI IT (terminal products and industry solutions), 5G (communication equipment and private network solutions) and Internet of Things ("IoT") (products and industry solutions), the Group's three major business segments, increased steadily and showed a positive development trend. The Group's revenue for the Period increased by approximately 37.5% to approximately RMB366.15 million (six months ended 30 September 2021: approximately RMB266.28 million), which was mainly benefited from the significant growth in the revenue of intelligent terminal products sales business of the Group for the Period as driven by the economic recovery, while the Group's gross profit also increased by approximately 14.2% to approximately RMB76.33 million (six months ended 30 September 2021: approximately RMB66.85 million). Gross profit margin was 20.8% (six months ended 30 September 2021: 25.1%), mainly due to the increase in the revenue from the intelligent terminal products sales business, which has a relatively low gross profit margin, from 77.5% of the Group's total revenue for the corresponding period of 2021 to 85.7% for the Period. The Group's profit attributable to owners of the Company increased by approximately 69.1% to approximately RMB7.39 million for the Period (six months ended 30 September 2021: approximately RMB4.37 million), which was mainly due to the significant growth of revenue and gross profit during the Period as driven by the substantial increase in the revenue from the intelligent terminal products sales business during the Period, as compared with 2021, and also the decrease in the Group's administrative expenses, finance costs, research and development expenses and income tax expenses during the Period as compared with the corresponding period of 2021. Huge Room for Domestic Substitution and Strong Demand for ITAI Industry The central government has incorporated the ITAI industry into the national development strategy, and has continuously introduced relevant policies to support the development of the industry, indicating that the PRC's ITAI industry has entered into an accelerated stage of domestic substitution. At present, the ITAI industry presents a huge market space and unprecedented market opportunities. Benefiting from the central and local governments' efforts to promote ITAI procurement, the scale of ITAI industry in the PRC has been growing rapidly, and the Group has penetrated into various key industries such as finance, telecommunications and energy. The market demand for purely domestically-produced software and hardware has accelerated, driving the development of the entire industry chain into a new "rillion-dollar industry".Actively Seizing the Opportunity of Domestic Substitution, the Demand for Major Business Segments Increased Steadily During the Period, intelligent terminal products sales business remained as the main source of the Group's income, accounting for approximately 85.7% of total revenue. During the Period, the Group focused on the development, production and sales of customised IoT smart terminals to customers. Benefiting from the recovery of economic activities, revenue from the intelligent terminal products sales business increased by approximately 52.2% to approximately RMB313.87 million (six months ended 30 September 2021: approximately RMB206.26 million).With regards to software development, the Group plans and designs the software system frameworks and function lists for customers, and provides customised software application development services based on their business and management needs. Leveraging on its strong software development capabilities, the Group has been providing quality software application development services to serve customers in different industries for many years. Affected by the decrease in demand for seasonal services, the segment recorded a revenue of approximately RMB46.16 million for the Period (six months ended 30 September 2021: approximately RMB54.92 million), accounting for 12.6% of the Group's total revenue.With regards to system integration and system maintenance services, the Group's segmental revenue were approximately RMB0.26 million (six months ended 30 September 2021: approximately RMB20,000) and approximately RMB5.86 million (six months ended 30 September 2021: approximately RMB5.08 million) respectively.Boosted ITAI Business Development to Grasp the Market Gap of the ITAI Industry In addition, the Group entered into a memorandum of understanding, an investment agreement and a supplemental agreement on the "IBO Technology Intelligent Manufacturing Industrial Park Project*", and also formed a joint venture with Fucheng District People's Government during the Period. The "IBO Technology Intelligent Manufacturing Industrial Park Project" is the first time that the Group has cooperated with the national government to launch an intelligent manufacturing industrial park project, proving that the Government is optimistic about the prospect of ITAI industry. It also marks a significant milestone for the Group since its entry into the ITAI industry in 2020, as a sign that the Group's development in ITAI industry has been widely recognised by the government.The "IBO Technology Intelligent Manufacturing Industrial Park Project" is to be invested in three phases. The investments in Phase I, Phase II and Phase III are projected to be RMB1.5 billion, RMB2 billion and RMB7 billion respectively. The project will accelerate the launch of domestically-produced products. For Phase I of the project, approximately 200,000 square-meter factories and ancillary facilities will be built. Approximately 2.5 million units of notebook computers, all-in-one computers, highly integrated desktop computers, cloud terminals and other ITAI terminal products can be produced annually when full production capacity of Phase I is reached. A high-end ITAI industrial park will be built in Phase II, and 5G equipment, energy storage equipment industrial park project, etc. will be built in Phase III. Moreover, Fucheng District People's Government will invest RMB400 million through Sichuan Fuchuang Development Group Limited, a state-owned company, to form a joint venture with a subsidiary of IBO Technology to collobrate in the "IBO Technology Intelligent Manufacturing Industrial Park Project".The Board believes that the "IBO Technology Intelligent Manufacturing Industrial Park Project" will build a "closed-loop" ecosystem of the ITAI industry, so as to strengthen the supply chain synergy, production and manufacturing synergy and technology synergy of upstream and downstream enterprises. The base will be a key project to promote the Group's future development. It is expected to improve the Group's production capacity, build strong product delivery capabilities and optimise cost management, which will help the Group continue to boost the development of domestically-produced ITAI industry and product research and development, accelerate the launch of products, in order to meet the strong demand for ITAI products from the market and the government. Thus, it will help the Group actively grasp the market gap and unprecedented market opportunities.Entered the Quantum Computing Industry, Expanding Revenue StreamFurthermore, the Group announced that it will enter into a cooperation agreement with Shenzhen SpinQ Technology Co., Ltd. in respect of quantum computing cloud platform development project. Centering on practical applications of quantum computing products and technologies by enterprises engaged in such areas as e-government, scientific research institutes, education, finance, and biopharmaceuticals in cloud computing, big data, and other areas, the parties will pursue cooperation on the development of domestically-produced quantum computing cloud platform project. Both parties have determined to form strategic partnership. They will both demonstrate complementary technological and marketing prowess, and will continue to integrate their respective advantageous resources, increase customer values, and achieve mutually beneficial cooperation. Leveraging on the technical advantages over quantum computing systems and application ecosystems of Shenzhen SpinQ Technology Co., Ltd., the Group is expected to enter the quantum computing industry through this cooperation, further expanding its revenue stream. Synergistic Advantages of Three Major Businesses to Build a MoatLooking ahead, leveraging on the close connection and synergy among the three major business segments, namely 5G, ITAI and IoT in the aspects of underlying technology, application technology, supply chain, project and business model, the Group will strive to seize the opportunities in the golden market, further strengthen and expand its own business, promote the healthy development of its business through multiple channels, actively identify suitable merger and acquisition targets that can create strong synergies with its existing principal business to support the Group's operation and rapid development. IBO Technology will continue to pursue breakthroughs, research and develop and launch more new high-quality products and services, so as to deliver better results and make positive contribution to the development of ITAI and 5G industries in China. * For identification purpose onlyAbout IBO Technology Company LimitedIBO Technology Company Limited (Stock code: 2708.HK), a leading digital solutions provider, is principally engaged in providing 5G communication equipment and private network solutions, ITAI terminal products and industry solutions, IoT products and solutions, as well as industrial digital solutions in the PRC. The Group's businesses mainly cover four areas, namely (i) intelligent terminal products sales; (ii) system integration; (iii) software development; and (iv) system maintenance services. With nearly 20 years penetration in the IoT industry, the Group serves customers from both the public and private sectors in the PRC, including government authorities, large-scale state-owned enterprises and private enterprises. In 2022, the Group cooperated with the People's Government of Fucheng District, Mianyang City, Sichuan Province to develop an intelligent manufacturing industrial park project, striving to promote the development of ITAI products in future. For more details, please visit: http://www.ibotech.hk/ Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Consortium of Japan partners successfully promote domestic production and cost reduction for 5G core technology, the basis for next-generation communication standards JCN Newswire

Consortium of Japan partners successfully promote domestic production and cost reduction for 5G core technology, the basis for next-generation communication standards

November 24, 2022
TOKYO, Nov 24, 2022 - (JCN Newswire via SEAPRWire.com) - The University of Tokyo, Internet Initiative Japan (IIJ), APRESIA, and Fujitsu Limited have successfully developed Open Source Software for the Private 5G/6G Mobile System, realizing a domestically produced, low-cost 5G core network (5GC), the core technology of the 5G mobile network. The initiative was conducted by the partners as part of NEDO's Research and Development Project of the Enhanced Infrastructures for Post-5G Information and Communication Systems Feasibility Study (Contracted).Figure 1: Image of the Newly Developed 5GCFigure 2: Image of Private 5G System Commercialized by APRESIA and FujitsuFigure 3: Image of Multiple Private 5G Systems Promoted by IIJ5GC software plays a central role in controlling cell phone networks, but the need for domestic production and cost reduction represents ongoing challenges to making related technologies, like private 5G, a reality. With the development of this new technology, IIJ, APRESIA, and Fujitsu developed a practical version of 5GC based on Open Source Software with commercial-level functionality, performance, and stability based on Open Source Software. The University of Tokyo contributed a user plane function (UPF) that handles more advanced data transfer and route selection by combining 5GC with previously known properties and have applied for a new patent.The partners anticipate that the eventual, real-world deployment of this technology will allow users to introduce private 5G systems at lower cost for use in practical settings, leading to the wider adoption of private 5G in various industries. Combining multiple private 5G networks and 5G services provided by major telecommunications carriers will ultimately make it possible to deliver more versatile communication environments than individual private 5G networks alone.1. Overview5G cell phone networks are beginning to be used not only as a means of communication, as is the case for phones and smartphones, but also in critical infrastructure systems that support society, such as payments and logistics. Although the technology that makes up mobile networks is based on a common global standard, most of the communications equipment used in actual mobile networks is manufactured by vendors outside of Japan, which also hold many of the patents for intellectual property for related technologies. This represents a possible risk to market competition and economic security, making it an important priority for Japanese companies and researchers to proactively develop products and technologies in anticipation of post-5G and next-generation communication standards that are expected to emerge after 2025. Going forward, it is hoped that industry-academia-government collaboration will lead to the development of practical-level communication devices and the resolution of issues.Against this backdrop, in Japan, NEDO has conducted its "Research and Development Project of the Enhanced Infrastructures for Post-5G Information and Communication Systems (1) /Feasibility Study (Contracted)" surrounding the theme of "Open-source software development for Local5G/6G mobile systems." The initiative, which lasted two years from October 2020 to October 2022, resulted in the successful development of core technology by the partners for 5G mobile network technology that can be domestically produced at low cost.2. Key outcomes of this projectDevelopment of 5G Core network (2)Unlike 5GC for major telecommunications carriers, which is designed to manage tens of millions of lines, the 5GC developed through this project is a compact implementation that can efficiently manage several to several thousand lines. Development based on Open Source Software (3) has also decreased the burden of intellectual property costs. This makes it suitable for environments where many small-scale 5G systems, such as private 5G, are to be built. Because it is implemented as software that runs on Commercial Off-The-Shelf (COTS), 5GC can also be cloud-based for maximum utilization.Open and closed strategies The 5GC developed in this project is based on free5GC, which is being developed by engineers around the world as Open Source Software. In general, Open Source Software is superior in terms of transparency because all source code is publicly available, so it is possible to check for the inclusion of programs with malicious intentions. On the other hand, some Open Source Software lack the necessary functions for commercial use, and there are technical issues such as insufficient verification of performance and stability.In this project, based on the knowledge of IIJ, which operates commercial networks, the partners added functions to free5GC, improved its performance, and verified its stability using technology from APRESIA and Fujitsu, which develop many commercial network products, and raised its quality to a level where it can be used as a commercial product. The ability for Japanese companies to provide highly practical 5GC with transparency is also important from the perspective of economic security.This project newly defines the open and closed strategy, establishing collaborative areas in which the results of development are returned to society (open) and competitive areas that are occupied (closed) to maintain an advantageous position in the market environment. As an outcome belonging to the collaborative area, the free5GC improvement areas implemented within the project are being fed back to the free5GC development team, and the outcomes are available worldwide. In this manner, the presence of Japanese companies in an open development environment is significant not only in the post-5G era, but also in taking the initiative for next-generation communication standards. For results in the competitive area, the partners applied for patents for the university's latest findings to help raise the level of Japan's industrial competitiveness, acquire intellectual property to compete in the global marketplace, and contribute to the revitalization of the economy. They are also paving the way for business models that transfer technology from universities to venture companies.3. Future plansAPRESIA and Fujitsu will continuously release solutions for private 5G networks that combine the 5GC technology developed through this project and 5G base stations and terminal equipment manufactured by each company. IIJ will also promote the development of communication services that can use multiple private 5G networks using 5GC developed through this project and public 5G networks provided by IIJ as a mobile virtual network operator (MVNO) through roaming. Furthermore, the University of Tokyo plans to supply the results of this development to an integrated private 5G system of a university-launched venture company.Going forward, the University of Tokyo will work together with companies to further promote industry-academic collaborations around the research of solutions and services that utilize the 5GC technology developed in this project, as well as conduct R&D on open base station equipment (NR: New Radio) that operates on the public cloud to accelerate efforts to further advance cloud-native 5G cell phone network technologies.(1) Research and Development Project of the Enhanced Infrastructures for Post-5G Information and Communication Systems :Project name: Research and Development Project of the Enhanced Infrastructures for Post-5G Information and Communication Systems Project period: From FY2019 Project summary: www.nedo.go.jp/activities/ZZJP_100172.html (in Japanease)(2) 5G core network:Post-5G core networks will require advanced technologies related to virtualization and computational resource management in order to efficiently process huge amounts of traffic with the least possible power consumption and at the lowest possible cost, while meeting the requirements of diverse services. Moreover, in order to meet the demand for low latency and high reliability, we may see a significant shift from processing in single huge data centers to cloud-based core networks that utilize multiple geographically dispersed computing resources in the future.(3) Open Source Software:The source code is open to the public and can be used, modified, and redistributed for either commercial or non-commercial use, and is actively being adopted by companies for commercial products and services, especially for general-purpose libraries.About FujitsuFujitsu's purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers in over 100 countries, our 124,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: Computing, Networks, AI, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$32 billion) for the fiscal year ended March 31, 2022 and remains the top digital services company in Japan by market share. Find out more: www.fujitsu.com. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)
More
Pertamina, ExxonMobil agree to develop CCS for decarbonization ACN Newswire

Pertamina, ExxonMobil agree to develop CCS for decarbonization

November 15, 2022
JAKARTA, Nov 15, 2022 - (ACN Newswire via SEAPRWire.com) - Pertamina and ExxonMobil have signed a cooperation agreement for developing carbon capture and storage (CCS) for cutting carbon emissions while supporting economic growth.Pertamina and ExxonMobil have signed a cooperation agreement for developing carbon capture and storage (CCS) as part of efforts to reduce carbon emissions while supporting economic growth. (ANTARA/Pertamina)"This collective agreement is a solid foundation for Indonesia to achieve Indonesia's net-zero target by 2060 or sooner," Coordinating Minister for Maritime Affairs and Investment Luhut Binsar Pandjaitan said on Monday.The Indonesian government is working on developing regulations that support carbon capture and storage (CCS) and starting discussions with governments in other regions, he added.Meanwhile, Pertamina's CEO and president director, Nicke Widyawati, said that the CCS development and decarbonization cooperation is in line with Pertamina's efforts to support the government's program to accelerate the energy transition and achieve the target of reducing emissions by 29 percent by 2030."The development of CCS technology is in line with Pertamina's commitment to implementing Environmental, Social, and Governance (ESG) in all lines of the company's business to encourage business sustainability in the future," she added.The fastest way to ensure the transition to new renewable energy and decarbonization in Indonesia is through partnerships, she emphasized. This is to answer the three global challenges, namely technology, finance, and human capital, at once.According to Widyawati, the application of CCS technology is expected to play an important role in reducing greenhouse gases in the atmosphere, which contribute to global warming, climate change, ocean acidification, and loss of biodiversity."The development of CCS technology has a double impact, in addition to reducing emissions while increasing national oil and gas production," she said.A joint study conducted by Pertamina and ExxonMobil has succeeded in finding the potential for carbon dioxide (CO2) storage of up to 1 billion tons in Pertamina's oil and gas fields.This large CO2 capacity can permanently store CO2 emissions across Indonesia at the current average for the next 16 years.In total, Pertamina is working on six CCS/CCUS projects by selecting fields that can be used as CO2 injection sites.The six potential sites are located in several offshore areas in Sumatra, Java, Kalimantan, and Sulawesi.The discovery of the great potential of CO2 has become an opportunity for the development of the CCS business and decarbonization efforts in Indonesia.Contact: Heppy Wulansari, Pjs. Vice President Corporate Communication, PT Pertamina (Persero)Mobile: +62 811-296-949, Email: heppy@pertamina.com, URL: https://www.pertamina.comWritten by: Katriana, Editor: Fardah Assegaf (c) ANTARA 2022 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Grand Ming Group Holdings Limited Announces Interim Results for the Six Months Ended 30 September 2022 ACN Newswire

Grand Ming Group Holdings Limited Announces Interim Results for the Six Months Ended 30 September 2022

November 12, 2022
HONG KONG, Nov 12, 2022 - (ACN Newswire via SEAPRWire.com) - Grand Ming Group Holdings Limited (the "Company" and together with its subsidiaries, the "Group", stock code: 1271.HK) today announces its interim results for the six months ended 30 September 2022 ("FH 2022/23").Highlights-- Revenue amounted to HK$4.92 billion, an increase of 7.4 times from the last corresponding period.-- Profit for the period was HK$1.41 billion, representing a year-on-year increase of 19.4 times.-- Declared payment of an interim dividend of 6.0 HK cents per share.-- Stay positive toward lucrative business of owning and operating data centres via expanding portfolio of developing two new centres in near future.-- Seize opportunity to increase land reserve for property development in Hong Kong.-- Continue to execute the plan for property development in Nanning, Guangxi Province, China.The Group's consolidated revenue increased by 7.4 times from HK$586.1 million for the six months ended 30 September 2021 ("FH 2021/22") to HK$4,920.1 million for FH 2022/23. The Group recorded a net profit for FH 2022/23 was HK$1,410.2 million, representing an increase of 19.4 times when compared to that of HK$69.2 million for FH 2021/22. Earnings per share was 99.3 HK cents (2021: 4.9 HK cents). The Group's underlying profit for FH 2022/23, excluding the change in fair value of investment properties, amounted to HK$1,414.3 million, representing an increase of 47.4 times as compared to an underlying profit of HK$29.2 million for FH 2021/22. Underlying earnings per share was 99.6 HK cents (2021: 2.1 HK cents). The significant increase in the Group's consolidated revenue and net profit in FH 2022/23 was primarily attributable to the handover of the pre-sold units of the residential project namely The Grand Marine to buyers during FH 2022/23.The Board declares to pay an interim dividend of 6.0 HK cents (2021: 4.0 HK cents) per share, payable on 15 December 2022 to shareholders whose names appear on the Company's register of members on 2 December 2022.The Group's first residential property development project "The Grand Marine" at Tsing Yi, the New Territories consisted of two residential towers with 776 residential units, together with car parks and clubhouse facilities. It provides a saleable area of approximately 345,000 square feet. The property's pre-sale which began in November 2019 received applauding sentiment and over 92% of the residential units had been pre-sold. The certificate of compliance for The Grand Marine was obtained in March 2022. Handover of the pre-sold units to buyers subsequently commenced in April 2022, with revenue of HK$4.77 billion recognised during FH 2022/23.The data centre leasing business was in good shape maintaining a healthy growth. Revenue derived from this segment increased by 23.9% to HK$113.9 million in FH 2022/23, primarily driven by the increased utilisation of data centre spaces by existing and new customers. The Group on the other hand executes the plan to expand the data centre network by developing the two greenfield sites at No.3 On Kiu Street and No.8 On Chuen Street in Fanling, the New Territories into two new high-tier data centres with an estimated gross floor area of approximately 185,000 square feet in aggregate. The development is targeted to be delivered in mid-2025 and mid-2026 respectively.In FH 2022/23, revenue derived from the construction business decreased by 90.2% to HK$29.7 million, which recorded a significant drop due to substantial decrease in revenue recognized during the period under review from the completed construction project at Kai Tak.The Group's another development project in its heatmap, located at No. 41, 43 and 45 Pau Chung Street in To Kwa Wan, Kowloon is now named "The Grands". The site is being redeveloped into a 25-storey residential tower with 76 units and clubhouse facilities over two levels of shops covering a total gross floor area of approximately 31,000 square feet. The topping-out of the superstructure works had been completed and the interior fitting-out works are currently in progress. Preparation works for the pre-sale are also commenced. The project is scheduled to be completed in the first half of 2023.For the site at No.1 Luen Fat Street, Fanling, the New Territories, the Group plans to develop into a residential-cum-retail complex with a total gross floor area of approximately 36,000 square feet. The land exchange application to convert the use of land is under processing. Foundation works has started, and the development is scheduled to be completed in mid-2025. Upon completion of the redevelopment of the site, the completed properties will be sold to generate revenue for the Group.The Group's luxury residential project, CRISTALLO, at No. 279 Prince Edward Road West, Kowloon was well sold. As of September 2022, 15 units out of the total 18 units had been sold.The Group expands into Mainland China via acquiring its first land parcel through government public auction which is located at Guangxi-ASEAN Economic and Technological Development Zone, Wuming District, Nanning City, Guangxi Province with a site area of approximately 574,000 square feet in July 2021. It is planned to develop the land into a luxury residential project under the theme of leisure and healthy lifestyle, comprising high-rise apartment units, villas, retail shops and a wellness centre. Target customers will be the elderly and retirees and their families. The estimated gross floor area of the proposed development is approximately 1,100,000 square feet. Site investigation had substantially been completed. Application for building plan approval is under preparation.Mr. Chan Hung Ming, Chairman and Executive Director of Grand Ming Group Holdings concluded, "I am pleased to share that we have made a strong growth and achieved a record-high revenue and net profit from our right strategy of making the Group to be a property developer, despite the challenging global environment with persistent pandemic impact, interest rate hike and high inflation. Demand for our both development property and data centre portfolio remain resilient, and our brand is well oriented to capture growth opportunities. In the midst of uncertain economic outlook, we remain cautiously optimistic on the short term and confident on the long-term prospects of the local residential property market. We will keep on identifying and securing opportunities to increase land bank on the backdrop of our sound financial position. We also commit to providing comprehensive and reliable services to our data centre customers. Apart from upgrading the existing iTech Tower 1 & 2, the two new data centres in Fanling are designed and to be equipped to accommodate customers with high power requirement. Our new strategic direction of developing property in Mainland China will continue to leverage our distinctive operating capabilities and seasoned experience to seize the attractive growth opportunities."About Grand Ming Group Holdings Limited (Stock code: 1271.HK)The Group is principally engaged in the business of building construction, property leasing and property development. As a local wholesale co-location provider of high-tier data centres, the Group is one of the dedicated service providers in Hong Kong which owns and uses the entire building for leasing to customers for data centre use. Its clientele includes multinational data centre operator, telecommunications company and financial institutions. The Group operates two high-tier data centre buildings, namely iTech Tower 1 and iTech Tower 2. It also acquired two pieces of land in Fanling, the New Territories for developing into two high-tier data centres. Furthermore, the Group launches a residential development project namely "The Grand Marine" at No.18 Sai Shan Road, Tsing Yi, as well as a luxury residential project, Cristallo, at No.279 Prince Edward Road West, Kowloon. A new residential-cum-retail development project namely "The Grands", which is located at No. 41, 43 and 45 Pau Chung Street, To Kwa Wan, Kowloon with a total gross floor area of approximately 31,000 square feet, is well underway and scheduled to be completed in mid-2023. Besides, a site located at No.1 Luen Fat Street, Fanling, New Territories, is planned to develop into a residential-cum-commercial project with total gross floor area of approximately 36,000 square feet and target completion at mid-2025. In Mainland China the Group owns a piece of land at Guangxi-ASEAN Economic and Technological Development Zone, Wuming District, Nanning City, Guangxi Province for development into a luxury residential project comprising high-rise apartments, villas, retail shops and wellness centre with an estimated gross floor area of approximately 1,100,000 square feet.Media Contacts:Angel YeungJovian Communications LtdEmail: news@joviancomm.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Novotech Chairs BioCentury Summit Workshop on How to Build and Finance an East-West MRCT Strategy ACN Newswire

Novotech Chairs BioCentury Summit Workshop on How to Build and Finance an East-West MRCT Strategy

November 11, 2022
SYDNEY, AU, Nov 11, 2022 - (ACN Newswire via SEAPRWire.com) - Novotech, the leading Asia Pacific biotech specialist CRO, is sponsoring BioCentury-BayHelix East-West Summit 2022, and Novotech's Chief Commercial Officer Barry Murphy is Session Chair for the expert panel on How to Build and Finance an East-West MRCT Strategy Workshop at the Summit (14-16 November 2022).Novotech is sponsoring the Networking Reception and Dinner.Workshop details:Global Development Workshop: How to Build and Finance an East-West MRCT StrategyNovember 15, 20222:30 PM - (PACIFIC TIME ZONE) BioCentury-BayHelix East-West Summit 2022https://conferences.biocentury.com/china-healthcare-summit/schedulePanelists are:- PATRICIA KEEGAN, M.D.: Chief Medical Officer, Junshi Biosciences- KE LIU, M.D., PH.D.: Chief Development Officer, Marengo Therapeutics- ROGER LUO, PH.D.: Chief Development Officer, Overland Pharmaceuticals- PEONY YU, M.D.: Chief Medical Officer, Apollomics Inc.Novotech has significant real-world experience in East-West MRCT strategy after more than 2 decades managing clinical research programs for biotechs across Asia Pacific and the US.Commenting on Novotech's experience, Chief Commercial Officer Barry Murphy said the right drug development pathway supports investor attraction and a successful clinical program."Local regulatory knowledge and expertise will accelerate early clinical programs, while a global perspective with a focus on US FDA and NMPA requirements, will support key market approvals. Strategies for an East-West MRCT include:- Companies should engage with the US FDA and NMPA early to confirm guidance on their clinical roadmap.- Biopharma companies should take advantage of China's revised regulatory framework around acceptance of foreign clinical trials data for drug approval, making it easier for foreign companies to enter the Chinese market. - For biopharma companies looking to enter China, China's pharmaceutical market has advantages such as conducting first-in-human trials (FIH) and utilization of overseas clinical trial data for clinical trial application (CTA) filing, leveraging expedited clinical development pathways for accelerating the approval process; implementation of the Marketing Authorization Holder (MAH) system, favourable government policies to enhance domestic and global innovation encourages foreign direct investments (FDIs) in R&D that benefit the overseas companies.Novotech regularly produces expert reports on East-West strategies. A new publication is now available for international biotechs considering China for their clinical research, as well as China biotechs conducting research in China.The report details regulatory requirements for biotechs including NDA and IND processes as well as ex-US research guidance for a successful US FDA approval pathway. Download whitepaper here https://novotech-cro.com/whitepapers/china-biotech-landscape-opportunities-china-and-path-usfda-approvalNovotech, with experienced clinical teams in China and the US, can provide the relevant regulatory knowledge and drug development pathways specifically designed to support the US FDA and NMPA approval process, avoiding delays and additional costs.Novotech has operations across the Asia Pacific and the US offering a unique and unparalleled suite of CRO services for early to late-phase biotech clinical research. The company has decades of biotech drug development experience, exceptional site and investigator relationships, access to vast patient populations, and a project management approach focused on problem-solving, ownership, and flexibility. Consistent investment in advanced training and technology systems combine to deliver a specialist full-service biotech CRO solution.Novotech has recently been benchmarked as a top 10 CRO among the world's leading CROs, is a finalist in the prestigious Scrip awards, and has just been awarded the Gene & Cell Therapy Excellence Award. In Asia Pacific Novotech has more than 50 Leading Site Partnership agreements with major medical research institutions which delivers exclusive benefits for sponsors.About Novotech Novotech is the leading Asia-Pacific biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas. Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit https://novotech-cro.com/contactMedia Contactcommunications@novotech-cro.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
SinoMab Announces Appointment of Mr. Shanchun WANG as the President (China) of the Company ACN Newswire

SinoMab Announces Appointment of Mr. Shanchun WANG as the President (China) of the Company

November 4, 2022
HONG KONG, Nov 4, 2022 - (ACN Newswire via SEAPRWire.com) - SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that, Mr. Shanchun WANG has been appointed as the President (China) of the Company. Mr. Wang will mainly be responsible for the China operation.Mr. Shanchun WANG, served as the executive director of Sino Biopharmaceutical Limited (stock code: 1177) and the president of Chia Tai - Tianqing Pharmaceutical Group Co. Ltd., joined SinoMab lately as the President (China) of the Company. Mr. Shanchun WANG has rich experience and practical achievements in corporate strategic management, organizational management, innovation research and development and product commercialization. He is a specialist that granted the special government allowances of the State Council and awarded as a national model worker, a Jiangsu Province Technology Advanced Worker, a Jiangsu Province Model Labour, a winner of the Shanghai Technology Advancement First Honour Award, a Jiangsu Province Outstanding Entrepreneur, a Jiangsu Province Young and Middle-aged Expert with Outstanding Contribution, a Jiangsu Advanced Individual with Outstanding Contribution in Manufacture etc. Mr. Shanchun WANG said that: "Under the leadership of Dr. Shui On LEUNG, SinoMab has gathered a very strong R&D force, forged a unique B-cell therapeutic platform, and prospectively launched a pipeline with a series of potential key products, with truly internationally recognized original innovation strength. At the same time, SinoMab's dedication to the field of autoimmune diseases and its vision of growing into a global leader in novel treatments of immunological diseases is highly consistent with the development model of my service enterprises in the past, which is also an important reason why I chose to join SinoMab." Dr. Shui On LEUNG said that: "It is a great pleasure to have Mr. Shanchun WANG joining the Company. Our Group has been engaging extensively in the field of autoimmune disease and with the mission of growing into a global leader in the novel treatments of immunological diseases. We have a strong research and development capabilities. Leveraging on our Group's B-cell therapeutic platform, Alarmins-pathway therapeutic platform and selective T-cell therapeutic platform, the Group has a strategic plan in expanding and diversifying our product pipeline. We believe that Mr. Wang's rich experience in the pharmaceutical industry for more than 30 years, and as one of the leaders in the biotech industry in China, will help expediting the Company's development from a global drug research and development enterprise to a biopharmaceutical company bearing commercialization capabilities and international perspective. Mr. Wang's engagement as the President (China) of the Company while also subscribing shares of the Company also reflects the confidence and commitment of Mr. Wang and our senior management towards the long-term and sustainable growth of the Group, and the continuous support of our senior management will be beneficial to the long-term business development of the Group."The Company entered into a subscription agreement with Mr. Wang earlier. Pursuant to the subscription agreement, Mr. Shanchun WANG conditionally agreed to subscribe for and the Company conditionally agreed to allot and issue 14,340,000 subscription shares. This reflects his confidence and commitment towards the long-term and sustainable growth of the Group. About SinoMab BioScience LimitedSinoMab BioScience Limited (stock code: 3681.HK) is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company's flagship product SM03 is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis (RA) and is currently in Phase III clinical trial for rheumatoid arthritis in China, which has been recognized as one of the significant special projects of Significant New Drugs Development of the Twelfth Five-Year Plan Period and the Thirteenth Five-Year Plan Period. In addition, the Company possesses other potential first-in-target and first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), pemphigus, non-Hodgkin's lymphoma (NHL), asthma, and other diseases with major unmet clinical needs. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
“New Life in the GBA” Lucky Draw by Greater Bay Area Homeland Youth Community Foundation Concluded with 521 Happy Winners ACN Newswire

“New Life in the GBA” Lucky Draw by Greater Bay Area Homeland Youth Community Foundation Concluded with 521 Happy Winners

October 27, 2022
HONG KONG, Oct 27, 2022 - (ACN Newswire via SEAPRWire.com) - With its tremendous development, the Guangdong-Hong Kong-Macao Greater Bay Area (GBA) offers endless opportunities to Hong Kong Youth. The "New Life in the GBA" lucky draw launched by the Greater Bay Area Homeland Youth Community Foundation (the Foundation) ran from April to September this year aimed to support the development of young people in Hong Kong in establishing new lives in the GBA. The lucky draw received positive responses from young Hong Kong residents aged between 18 to 45. All eligible participants held a valid Mainland Travel Permit for Hong Kong and Macao Residents, had successfully registered as a YO PLACE member and held a "GBA Youth Card". 521 prizes were drawn live at YO PLACE yesterday on 25 October.We were pleased to have Mr Tommy Yuen Man-chung, Commissioner for the Development of the Guangdong-Hong Kong-Macao Greater Bay Area, Mr Bunny Chan Chung-bun, Hong Kong Delegate to the National People's Congress, and Mr Daryl Ng Win-kong, Chairman of Greater Bay Area Homeland Youth Community Foundation as the officiating guests, as well as Mr Nicholas Chan Hiu-fung, Honorary Legal adviser of the Foundation, Partner of Squire Patton Boggs and Mr Chris Mo Ying-wai, Partner of PricewaterhouseCoopers Hong Kong to witness the occasion. 521 winners were announced after the lucky draw, in which the Grand Prize winner received a decorated 3+1 bedroom residential apartment with GFA of 105m2 at Empyreal-Bay Zhongshan, valued at approximately HKD2.5 million, sponsored by Ng Teng Fong Charitable Foundation. Other prizes included 20 GBA living expenses spending credits of HKD20,000, and 500 GBA living expenses spending credits of HKD1,000, adding to a total of HKD900,000 being given away. Each of the rest of participants also received a transportation allowance of HKD100.The Foundation Supports Hong Kong Youth in Embracing Development Opportunities in the GBA With a total population of over 86 million, and an approximate area of 56 thousand square kilometres, the GBA is where the most open and vibrant markets are situated, and is of great significance to China's implementation of innovation-driven development and reform. According to the research data from the Hong Kong Trade Development Council, the GDP of the GBA has reached US$1,958.14 billion in 2021, showing extensive development potential of the GBA. Hong Kong has always been committed to integrating into the national development with the GBA as the entry point, in addition to consolidating traditional industries, the city has also strived to develop new businesses in innovation technology as well as art and culture. Mr Tommy Yuen Man-chung, Commissioner for the Development of the Guangdong-Hong Kong-Macao Greater Bay Area said, "Over the past three years since the promulgation of the Outline Development Plan for the Guangdong-Hong Kong-Macao Greater Bay Area, we have witnessed the continual development of the GBA. Many Hong Kong young people are taking the opportunities to work and develop their career in the Mainland cities of the GBA. The latest Policy Address has announced the regularistion of the GBA Youth Employment Scheme to encourage participating enterprises to recruit and deploy local university graduates to work in Hong Kong and other Mainland cities of the GBA, so that young people can better understand and grasp the opportunities of GBA development, enhance their awareness of the country's development, and fulfil their dream."Mr Daryl Ng Win-kong, Chairman of the Greater Bay Area Homeland Youth Community Foundation said, "The Central and Hong Kong government have always placed great importance in the development of Hong Kong youth within the GBA. As announced in the Policy Address last week, the Hong Kong government would set up a "Steering Group on Integration into National Development" to carry forward more cross-border initiatives, enhance communications with Mainland authorities and formulate strategic plans for Hong Kong to dovetail with the "14th Five-Year Plan" and the GBA development. With such immense opportunities, the Foundation will continue to organise diverse activities to encourage Hong Kong youth to seize the opportunities in the GBA while leveraging on the advantages of "One Country, Two Systems", and at the same time contribute to the development of Hong Kong and Mainland China."The full winner list has been published on the website of the Foundation (www.gbayouth.org.hk) and YO PLACE (http://www.yoplace.org.hk/) on 26 October.Trade Promotion Competition Licence No.:55633-6 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
ONERHT partners Democratic Republic of Congo for sustainable economic development and growth ACN Newswire

ONERHT partners Democratic Republic of Congo for sustainable economic development and growth

October 25, 2022
SINGAPORE, Oct 25, 2022 - (ACN Newswire via SEAPRWire.com) - Sustainability consultancy RHT Green and strategic advisory firm RHT Consulting Asia have entered into a Memorandum of Understanding (MOU) with the Ministry of Environment and Sustainable Development of the Democratic Republic of Congo (DRC) to support the implementation of multisectoral sustainable development projects in the central African country.H.E. Deputy Prime Minister for the Environment and Sustainable Development, Democratic Republic of Congo (centre), during her visit to ONERHT's office in SingaporeRHTLaw Asia and RHT Group of Companies, which includes RHT Green and RHT Consulting Asia (collectively "ONERHT"), welcomed the delegation of Her Excellency Eve Bazaiba, Deputy Prime Minister for the Environment and Sustainable Development of the DRC on her maiden visit to Asia.Hosted by ONERHT, Her Excellency was briefed on Singapore's approach to sustainable development and exchanged ideas for sustainable development and green growth in the DRC. The MOU marks the culmination of discussions between the parties on sustainable value creation strategies and efforts to design effective environmental policies for the DRC's sustainable economic development and growth. As appointed partners of the Democratic Republic of the Congo, RHT Green and RHT Consulting Asia will support the Ministry of Environment and Sustainable Development by advising on planning, policies, regulations, and solutions to address the DRC's challenges across economic development, free trade and environmental protection. Mr Wee Boon Siong, Chief Executive Officer of RHT Green, said, "We are happy to work together with the DRC government on environment and sustainability. The DRC has a huge rainforest, the 2nd largest in the world, next to the Amazon, and it is an important carbon sink for our planet. It also has large mineral reserves which are the necessary components of many renewable industries. Cobalt, copper, nickel, lithium and rare earth elements (REEs) are all essential for producing electric vehicle batteries, harnessing solar power, wind energy, and other applications to reduce the reliance of consumers and industries on fossil fuels. These are important factors to take into account for planning and policies."The MOU also focuses on examining the DRC's policies and regulations, establishing a free trade zone, and exploring sustainability technology solutions. It reflects potential synergies between Singapore's track record in balancing finance, economic and sustainability solutions, and the resource-rich DRC, offering more opportunities for future collaboration and partnerships.Mr Victor Tay, Group Chief Executive Officer of RHT Consulting Asia said, "Singapore's economic development experience spanning close to 60 years since its Independence is a case study on how countries must find an economic strategy that aligns with their competitive advantage in the global economic environment. Along the way, Singapore had to address the challenges while adapting to trends in the global economic environment, evolving from a transhipment hub to become a manufacturing gateway to Asia, globalised financial hub, and now a Fintech hub while balancing emphasis on ESG (Environmental, Sustainability and Governance)." Mr Tay added, "We will share Singapore's economic development experience and the institutionalised knowledge of the last six decades with the DRC, taking into account its competitive advantages as well as the challenges unique to it." About ONERHTThe ONERHT Universe is an integrated multidisciplinary platform of professional services. Collaborating as ONE, we seek to be a beacon of growth for our clients, stakeholders and communities, empowering them to achieve purposeful growth in Asia and beyond. RHTLaw Asia LLP is a Singapore law practice registered as a limited liability law partnership in Singapore. A leading full-service firm with industry focus, it has presence in 16 jurisdictions through the ASEAN Plus Group. In delivering innovative legal and commercial solutions, it collaborates with ONERHT through entities which are not affiliates, branches or subsidiaries of RHTLaw Asia LLP. For more information, please visit www.onerht.com Issued on behalf of ONERHTBy Waterbrooks Consultants https://www.waterbrooks.com.sg/For media enquiries, please contact:Elliot Siow+65 8375 0417elliot@waterbrooks.com.sg Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Clinical Research Opportunities in China and the Path to USFDA Approval – Whitepaper ACN Newswire

Clinical Research Opportunities in China and the Path to USFDA Approval – Whitepaper

October 25, 2022
SYDNEY, AU, Oct 25, 2022 - (ACN Newswire via SEAPRWire.com) - Novotech, the leading Asia Pacific biotech specialist CRO, and GlobalData have published the latest China biotech landscape analysis with expert guidance on pathways to USFDA approval for biotechs conducting research in China.Download whitepaper here https://novotech-cro.com/whitepapers/china-biotech-landscape-opportunities-china-and-path-usfda-approval The report was prepared for international biotechs considering China for their clinical research, as well as China biotechs conducting research in China, and the relevant processes required for USFDA approvals.Novotech's Vice President, Global Head of Clinical Services Dr. Yooni Kim said: "China presents exceptional clinical opportunities with vast populations and word-class research facilities and KOLs. This concise analysis of the pathway to USFDA approval expertly informs clinical stage biotechs about the China research benefits and how to manage any challenges. The report details the regulatory requirements for biotechs including NDA and IND processes as well as ex-US research guidance for a successful USFDA approval pathway. Novotech, with experienced clinical teams in China and the US, can provide the relevant regulatory knowledge and drug development pathways specifically designed to support the USFDA approval process, avoiding delays and additional costs."The key learnings from the report are:- Companies should engage with the USFDA early and formally to confirm guidance on their clinical roadmap.- China's clinical development regulations are aligned with the USFDA regulations and present significant benefits for biopharma companies.- Biopharma companies should take advantage of China's revised regulatory framework around acceptance of foreign clinical trials data for drug approval, making it easier for foreign companies to enter the Chinese market.- For biopharma companies looking to enter China, China's pharmaceutical market has advantages such as conducting first-in-human trials (FIH) and utilization of overseas clinical trial data for clinical trial application (CTA) filing, leveraging expedited clinical development pathways for accelerating the approval process; implementation of the Marketing Authorization Holder (MAH) system, favorable government policies to enhance domestic and global innovation encourages foreign direct investments (FDIs) in R&D that benefit the overseas companies.- Chinese biotech companies can enter developed markets in the US and Europe through strategic partnerships or by setting-up their own operations in these markets.Novotech has operations across the Asia Pacific and the US offering a unique and unparalleled suite of CRO services for early to late-phase biotech clinical research. The company has decades of biotech drug development experience, exceptional site and investigator relationships, access to vast patient populations, and a project management approach focused on problem-solving, ownership, and flexibility. Consistent investment in advanced training and technology systems combine to deliver a specialist full-service biotech CRO solution.Novotech has recently been benchmarked as a top 10 CRO among the world's leading CROs, is a finalist in the prestigious Scrip awards, and has just been awarded the Gene & Cell Therapy Excellence Award. In Asia Pacific Novotech has more than 50 Leading Site Partnership agreements with major medical research institutions which delivers exclusive benefits for sponsors.About Novotech Novotech is the leading Asia-Pacific biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas. Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit https://novotech-cro.com/contact Media ContactDavid JamesE: communications@novotech-cro.comAU: +61 2 8218 2144 USA: +1 415 951 3228Asia: +65 3159 3427 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
The Biotech Landscape Webinar: Market Trends, Priorities, Predictions, and Pathways to FDA Approval ACN Newswire

The Biotech Landscape Webinar: Market Trends, Priorities, Predictions, and Pathways to FDA Approval

October 17, 2022
SYDNEY, AU, Oct 17, 2022 - (ACN Newswire via SEAPRWire.com) - Novotech, the leading Asia Pacific biotech specialist CRO, and Endpoints News present a webinar for biotechs considering the clinical research opportunities in Asia Pacific and the regulatory pathways to achieving FDA approval.Novotech has operations across Asia Pacific and the US offering a unique and unparalleled suite of CRO services for early to late phase biotech clinical research.The webinar features regulatory affairs and investment leaders from North America and Asia Pacific who will discuss:- why biotech companies are increasingly exploring clinical opportunities in Asia Pacific to generate diverse, globally accepted clinical trial data- what actionable strategies can be implemented to leverage Asia Pacific's recruitment potential to accelerate your clinical development- how Phase 1 data from Australia is acceptable to the FDA and can be used to launch global drug development programs- deep insight into processes for designing and delivering a robust clinical program- biotech challenges and opportunities in the post-COVID environment with a focus on global investments and drug pipelinesRegister for the webinar here https://webinars.endpts.com/the-biotech-landscape-market-trends-priorities-predictions-and-pathways-to-fda-approval/October 18, 20221:00 pm - 2:00 pm EDTThe industry leaders presenting include:- Yi Larson, Chief Financial Officer of LianBio. Formerly Executive Vice President and Chief Financial Officer at Turning Point Therapeutics, Inc., and Goldman Sachs & Co. LLC, Managing Director of Healthcare Investment Banking- Kasey Kime, Director of Regulatory Affairs for Novotech's in-house consulting group, BioDesk- Dr. Jeanne M. Novak, President and CEO of CBR International Corp., a full-service product, clinical, and regulatory strategy group- Dr. Fred Cohen, a Co-Founder and Chairman of Monograph Capital Partners. He is also a Co-Founder and Senior Managing Director at Vida Ventures.Novotech has decades of biotech drug development experience, exceptional site and investigator relationships, access to vast patient populations, and a project management approach focused on problem-solving, ownership and flexibility. Consistent investment in advanced training and technology systems combine to deliver a specialist full-service biotech CRO solution.Novotech has recently been benchmarked as a top 10 CRO among the world's leading CROs, is a finalist in the prestigious Scrip awards, and has just been awarded the Gene & Cell Therapy Excellence Award. In Asia Pacific Novotech has more than 50 Leading Site Partnership agreements with major medical research institutions which delivers exclusive benefits for sponsors.About Novotech Novotech is the leading Asia-Pacific biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas. Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit https://novotech-cro.com/contactMedia ContactDavid JamesE: communications@novotech-cro.comAU: +61 2 8218 2144 USA: +1 415 951 3228Asia: +65 3159 3427 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
MHI Signs Statement of Cooperation with the State Government of South Australia on Development of Local Hydrogen Industry JCN Newswire

MHI Signs Statement of Cooperation with the State Government of South Australia on Development of Local Hydrogen Industry

October 14, 2022
TOKYO, Oct 13, 2022 - (JCN Newswire via SEAPRWire.com) - Mitsubishi Heavy Industries, Ltd. (MHI) signed a Statement of Cooperation on October 10 with the State Government of South Australia aimed at accelerating development of the local hydrogen industry. By proposing diverse solutions incorporating its Groupwide products, technologies and services, MHI looks to collaborate with South Australia in the state's transition to clean energy and development of a hydrogen economy.The Statement of Cooperation was signed by The Hon Peter Malinauskas MP, Premier of South Australia, and MHI Senior Vice President Osamu Ono, who concurrently serves as Chief Regional Officer of both the Asia Pacific and India as well as President of Mitsubishi Heavy Industries Asia Pacific Pte. Ltd. Specifically, MHI will propose solutions in the following areas: growing a globally competitive hydrogen export sector through the development of a hydrogen export strategy and strategic partnerships; fostering advances in new technologies and new industrial opportunities through research partnerships; projects that accelerate the development of large-scale industrial decarbonization programs; and developing near-term Australian domestic markets through the establishment of a hydrogen ecosystem.On signing the Statement of Cooperation, The Hon Premier Malinauskas MP expressed his hopes for the newly agreed partnership: "This Statement of Cooperation is a commitment from the State Government and industry partners to work together to accelerate the development of South Australia's hydrogen economy. South Australia is open for business and we are ambitious about hydrogen."MHI Group, by contributing to the development of a hydrogen value chain and the acceleration of industrial decarbonization in South Australia, looks to assist in driving the state's economic development and realizing a sustainable society.About MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world's leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)
More